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HUMAN CLONING AND EMBRYONIC STEM
CELL RESEARCH AFTER SEOUL; EXAMINA-
TION EXPLOITATION, FRAUD AND ETHICAL
PROBLEMS IN THE RESEARCH
TUESDAY, MARCH 7, 2006
HOUSE OF REPRESENTATIVES,
SUBCOMMITTEE ON CRIMINAL JUSTICE, DRUG POLICY,
AND HUMAN RESOURCES,
COMMITTEE ON GOVERNMENT REFORM,
Washington, DC.
The subcommittee met, pursuant to notice, at 2:05 p.m., in room
2247, Rayburn House Office Building, Hon. Mark E. Souder (chair-
man of the subcommittee) presiding.
Present: Representatives Souder, McHenry, Foxx, Schmidt, Wax-
man, Cummings, Watson, Ruppersberger, and Norton.
Staff present: Marc Wheat, staff director and chief counsel;
Michelle Gress, counsel; Malia Holst, clerk; Sarah Despres, Tony
Haywood, and Naomi Seiler, minority counsels; Earley Green, mi-
nority chief clerk; and Teresa Coufal, minority assistant clerk.
Mr. SOUDER. The committee will come to order.
Good afternoon, and I thank you all for being here. We are here
to examine the controversial research areas of human cloning and
embryonic stem cell research in light of the massive scientific scan-
dal in Seoul, South Korea. The scandal revealed that cloning re-
search widely acclaimed by proponents of human cloning and em-
bryonic stem cell research was a fraud. The scandal also brought
to light the disturbing fact that women were paid large sums of
money, and female assistants were coerced to donate, if that is the
word, their eggs for stem cell and cloning research in violation of
the Helsinki agreement.
Embryonic stem cell research and human cloning have been in-
tense political and societal issues for several years now. Embryonic
stem cell research requires the destruction of living human em-
bryos to harvest their stem cells, and research cloning involves the
deliberate creation of cloned human embryos for sole purpose of de-
stroying them to obtain their stem cells.
Proponents of these research areas promise they will result in
therapies and cures for a range of maladies and diseases, although
there has been little hard, empirical evidence to support these
claims. In fact, there are currently ho human clinical trials or
therapeutic applications using human embryonic stem cells.
And here I will quote British stem cell expert Professor Lord
Winston. ‘‘One of the problems is that in order to persuade the pub-
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2lic that we must do this work, we often go rather too far in promis-
ing what we might achieve. I am not entirely convinced that em-
bryonic stem cells will, in my lifetime, and possibly anybody’s life-
time, for that matter, be holding quite the promise that we des-
perately hope they will.’’
In contrast to the lack of any therapeutic applications using em-
bryonic stem cells, adult stem cells have provided therapeutic bene-
fits to human patients for at least 67 diseases and conditions.
Nonetheless, even in the absence of therapeutic applications for
embryonic stem cells, scientists have been very clear that they seek
to use stem cells from cloned human embryos as research tools.
Various critics of research cloning and embryonic stem cell re-
search have raised a myriad of objections to the research: The re-
search necessarily requires the destruction of living human em-
bryos, and in the case of cloning, the special creation of embryos
to be destroyed for their stem cells. The research necessarily re-
quires a large number of eggs, likely leading to the exploitation of
women in order to obtain their eggs for research. Advocates of re-
search cloning/embryonic stem cell research have created unjusti-
fied hype of the research that is not supported by current science,
but plays on the hopes of suffering patients.
These criticisms were borne out through the cloning research
conducted by Dr. Hwang, whose two groundbreaking papers were
retracted in January by the peer review journal that initially pub-
lished them. In addition to admitting that he deliberately fab-
ricated data, Hwang has also admitted the had lied about the cir-
cumstances under which he obtained eggs for his research, and
that in fact he had used eggs from junior scientists in his labora-
tory, a violation of the Helsinki declaration, as well as from paid
donors.
Skeptics of cloning and embryonic stem cell research consistently
warned that the sheer volume of eggs needed to pursue this line
of research would make it untenable, and virtually invite ethical
lapses by feeling the temptation to exploit women for their eggs.
Hwang’s research proves these fears. He initially claimed that he
had used only 185 eggs from female donors, which the scientific
community agreed was astonishingly low. But investigators now
believe that more than 2,200 eggs were obtained from 199 women.
Some donors who have since reported they were in desperate
need of money when they were offered and paid more than $1,400
for their eggs. And according to the South Korean National Bioeth-
ics Committee, the women had not been properly informed about
the risks to their health; 15 to 20 percent of those women devel-
oped ovarian hyperstimulation syndrome.
This scientific scandal is not an isolated incident of fabrication,
without real application to U.S. research efforts. Rather, it high-
lights the serious inherent political problems with research cloning
and embryonic stem cell research, including but not limited to ex-
ploitation, fraud, and coercion. The incident is a siren warning
against proceeding in these research areas without most cautiously
examining the societal costs necessarily associated with it. It would
be quite disingenuous to say otherwise.
Dr. Hwang was not a rogue scientist operating on the fringes of
his field with no oversight. He operated in an environment that
VerDate 11-MAY-2000 11:15 Dec 14, 2006 Jkt 000000 PO 00000 Frm 00006 Fmt 6633 Sfmt 6633 D:\DOCS\29580.TXT HGOVREF1 PsN: HGOVREF1
3proponents of cloning and embryonic stem cell research would like
to see adopted in the United States.
Dr. Hwang enjoyed the full support of his Government, which
vigorously promoted his research and funded it with tens of mil-
lions of dollars. Dr. Hwang also enjoyed enormous popular support
and had agreed to conduct his research under accepted ethical pro-
tocols. Dr. Hwang suspended his research until ethics laws were
enacted by the South Korean Government to demonstrate his will-
ing compliance with ethical standards. Dr. Hwang’s research was
conducted with the approval of two separate Institutional Review
Boards.
Nonetheless, Dr. Hwang’s actions represent the fulfillment of
every warning dismissed by proponents of research cloning and em-
bryonic stem cell research. Thousands of eggs were obtained
through payments and coercion. Many women suffered terrible side
effects after they were not properly informed of the risks. Not a
single embryonic stem cell line was obtained for the tens of mil-
lions of dollars in Government funds that were invested in re-
search. Anxious patients were misled about the research potential.
As stem cell researcher Ron McKay said about the hype involved
with embryonic stem cell research and distortions that are not ag-
gressively corrected by scientists, ‘‘To start with, people need a
fairy tale. Maybe that’s unfair, but they need a story line that’s rel-
atively simple to understand.’’
Our examination today will include an overview of current Fed-
eral policies related to these research areas. In particular, we will
hear what if any extra protections exist in the United States that
would prevent the type of widespread fraud or exploitation appar-
ent in the Hwang research. Also of special interest to the sub-
committee are the huge Federal grants that have been awarded to
the University of Pittsburgh researcher Gerald Schatten, who was
initially a co-author on one of Hwang’s fraudulent papers.
We will also hear from scientists, ethicists, women’s advocates,
and a patient advocate discuss these research areas and the known
problems associated with them.
On our first panel today, we have James Battey, Chair of the Na-
tional Institutes of Health Stem Cell Task force, and Director of
the National Institute on Deafness and Other Communication Dis-
orders; Bernard Schwetz, Director of the Office for Human Re-
search Protections; and Chris Pascal, Director of the Office of Re-
search Integrity.
The second panel consists of Dr. Richard Chole, Lindberg profes-
sor and chairman, Department of Otolaryngology, Washington Uni-
versity School of Medicine, St. Louis; Judy Norsigian, executive di-
rector, Our Bodies Ourselves, co-author of the book, ‘‘Our Bodies,
Ourselves’’; Ms. Diane Beeson, professor emerita, Department of
Sociology and Social Services, California State University, East
Bay; Mr. Richard Doerflinger, deputy director of secretariat for pro-
life activities of the U.S. Conference of Catholic Bishops; Ms. Debra
Mathews, assistant director for Science Programs, the Phoebe R.
Berman Bioethics Institute; and Mr. Joe Brown, Parkinson’s Action
Network State coordinator of Texas.
[The prepared statement of Hon. Mark E. Souder follows:]
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Mr. SOUDER. I will now yield to the ranking member, Mr. Elijah
Cummings, for his opening statement.
Mr. CUMMINGS. Thank you very much, Mr. Chairman.
Just yesterday a disgraced researcher, Dr. Hwang Woo Suk, ad-
mitted to prosecutors in South Korea that he had directed a subor-
dinate at the World Stem Cell Hub to fabricate research results.
This was the first admission by Dr. Hwang of his personal involve-
ment in fabricating claims made by his research team in two land-
mark papers on embryonic stem cell research published in the jour-
nal Science.
An investigative team at Seoul National University already had
determined that Hwang’s claims that he had developed 11 patient-
specific stem cell lines were in fact false. Dr. Hwang also acknowl-
edged that donated eggs used in the research were coerced from
junior members of his research team, and that some donors had
been paid large sums of money.
Throughout the investigation, however, Dr. Hwang acknowledged
no personal involvement in the scientific fraud. The fraud, exploi-
tation, and coercion for which Dr. Hwang has now admitted per-
sonal responsibility have earned him a resounding international re-
buke, including from Seoul National University where he was em-
ployed.
We can only hope that Dr. Hwang’s humiliation will serve to
deter other scientists who might contemplate seeking glory through
reporting fraudulent research, exploiting employees, and coercing
women to donate their eggs without informed consent.
In a sense, this case offers a measure of vindication to the broad-
er scientific community, demonstrating that it is difficult at best to
fool one’s peers for very long. Ultimately, the very nature of sci-
entific research tends to ensure that the truth about claims of
major scientific advances will surface.
In this very high profile case, questions have been raised as to
whether the claims of Dr. Hwang’s teams should have been verified
in advance by the publishing journal. In any case, it was mere
months before questions about Dr. Hwang’s methods and results
began to be called into question publicly. In fact, it is almost star-
tling how quickly many of Dr. Hwang’s claims have been thor-
oughly debunked, including yesterday through his own admission
of scientific fraud.
But the case of Dr. Hwang is no cause for celebration, even if op-
ponents of embryonic stem cell research seem to have difficulty
containing their glee. Opponents of the research have been eager
to portray the Korean scandal as proof that not only is this field
a research uniquely prone to ethical pitfalls, but that the research
itself is inherently bogus, offering nothing more than false hope to
patients.
Mr. Chairman, I join the mainstream of the United States and
the international scientific community in drawing a different lesson
and conclusion. This research, which will go forward with or with-
out the U.S. funding and oversight, needs the oversight that the
broader U.S. oversight would bring. Our own National Institutes of
Health is, without question, the entity best equipped to ensure that
embryonic stem cell research proceedings with scientific integrity
and in a way that ensures that women who donate their eggs are
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protected from coercion, exploitation, and undisclosed risk of ad-
verse health effects.
In the absence of strong Federal leadership, several States, in-
cluding California and Maryland, have taken steps toward adopt-
ing guidelines for conducting embryonic stem cell research. The
National Academy of Sciences has adopted guidelines as well.
But accountability for U.S. research will come with substantial
support for this research, and that support will also help to ensure
that important lines of research that offer relatively less profit po-
tential are pursued.
In closing, Mr. Chairman, it is important that we recognize that
fraud and ethical misconduct are hardly unique to science, and that
scientific fraud is not unique to embryonic stem cell research. Our
goal therefore should not be to use this controversy as a justifica-
tion to impede the search for important new knowledge that could
yield therapies and cures for many major diseases. Rather, our ob-
jective should be to ensure that as research in this important field
inevitably proceeds in and beyond the United States, it does so
with the benefit of strict Federal guidelines and a rigorous over-
sight.
With that, Mr. Chairman, I thank our witnesses for appearing
today, and I yield back.
[The prepared statement of Hon. Elijah E. Cummings follows:]
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Mr. SOUDER. I would like to yield to the vice chairman of the
committee, Mr. McHenry.
Mr. MCHENRY. Thank you, Mr. Chairman. Thank you so much
for holding this hearing today.
Recent events in South Korea have brought to light and global
attention has been brought to the issue of human cloning and em-
bryonic stem cell research. A number of concerns have been raised
surrounding this subject here and abroad, including the ethical di-
lemma of destroying life; fraudulent scientific procedures, as has
been mentioned by Ranking Member Cummings, as well as exploi-
tation of women. All these are very serious subject matters that we
must address here today in this hearing.
As a part of this discussion, it is important to make the distinc-
tion between human embryonic stem cell research and adult stem
cell research. Adult stem cells and the research derived from adult
stem cells do not destroy human life, and do not take the essence
of life from the host being; whereas in embryonic stem cell re-
search, that is the case. Life is taken from that fertilized egg, and
that life is destroyed.
Embryonic stem cell research is the purposeful creation of
human embryos destined to be destroyed for scientific research, in
this case, in the name of stem cell research. Adult stem cells have
provided therapeutic benefits and cures to 67 diseases and condi-
tions such as diabetes, damaged heart tissue, strokes, cancers, Par-
kinson’s, and spinal cord injuries, among others. We need to focus
in the successes of adult stem cell research, an ethical approach
that provides cures and therapies, instead of focusing on this all-
too-political, it seems, issue of embryonic stem cell research.
Beyond the fact that there are currently no clinical trials or
therapeutic applications using embryonic stem cells, there are a
number of complications due to this approach, such as immune re-
jections and the inability to obtain pure cultures. The fact that this
process is so inefficient means an outrageous number of eggs will
be required for this approach.
And I would like to hear from our panel today as to their esti-
mates on how many eggs would be required to actually move for-
ward with major cures and major therapies. Some have said that
even for a disease that touches 17 million people or 20 million peo-
ple, you would have to have roughly 850 million eggs harvested,
which means if you had 10 women willing to donate their eggs, you
would have to have about 85 million women in this country donate
their eggs.
It is a staggering sum. And this also goes back to the other issue
that is of major substance, and that is the exploitation of women,
which has been brought to light with the controversy and the fraud
perpetrated out of South Korea.
I would like to welcome our witnesses today. I thank you for tak-
ing the time to be here. And this issue today is not simply about
South Korean research fraud. It is about the larger issue of stem
cell research and what is an ethical, realistic, and moral approach
that moves science forward while keeping to ethics in medicine and
science.
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Thank you all again for being here today. And again, Mr. Chair-
man, thank you so much for your hosting this meeting today.
[The prepared statement of Hon. Patrick T. McHenry follows:]
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Mr. SOUDER. Thank you. I will now yield to the distinguished
ranking member of the full Committee.
Would you yield to Ms. Norton?
Ms. NORTON. I yield to the ranking member.
Mr. WAXMAN. Well, I thank you both very much for this chance
to make an opening statement.
We are going to hear testimony today about the ethical issues
around embryonic stem cell research and therapeutic cloning. In
particular, we will focus on the scandal in South Korea regarding
fraudulent research and abuses of research subjects.
Many opponents of stem cell research would like to use the
South Korean experience as a basis for banning embryonic stem
cell research. The story of Dr. Hwang’s fraudulent research in
South Korea is shocking because we rely on scientists to discover
the truth, not subvert it. We need to condemn the fraud, figure out
what happened, and learn how we can keep it from happening
again. And we need to make sure that this research is well-regu-
lated and thoroughly scrutinized.
But banning future stem cell research would be a gross over-
reaction. Unfortunately, though the vast majority of researchers
are honest, fraud sometimes occurs in scientific and medical re-
search. In fact, among Members of Congress, while most are hon-
est, there are some who are not.
In 1983, a cardiology researcher at Harvard was found to have
fabricated much of his data. In 1996, it was revealed that reports
of a re-implanted ectopic pregnancy by British physicians were
fraudulent. And in 2002, it was discovered that a rising star physi-
cist working on carbon-based semiconductors had fabricated most
of the data.
The answer to these instances of fraudulent research was not to
ban or deny funding for research on heart disease, ectopic preg-
nancy, and semiconductors. The right answer is to create and up-
hold high standards of oversight. When doubts emerge, disclosure,
investigation, and corrections must happen swiftly and openly.
That is the right response whether the fraud involves heart disease
or stem cell research.
We are also going to hear questions raised today about the poten-
tial benefits to be gained from various types of stem cell research.
Those who oppose embryonic stem cell research often claim that be-
cause we do not yet know what therapies it will yield, we should
not allow it to proceed.
That is a flawed line of reasoning. If we followed this to its log-
ical conclusion, it would mean that the Federal Government should
only fund research into cures and therapies that we already know
about. The argument also understates that we do know about em-
bryonic stem cells.
Decades of research have established the potential that these
cells hold for addressing serious illnesses such as Alzheimer’s, Par-
kinson’s, and even cancer. I say potential, not promise, because
there are no promises in any form of research. But what scientists
have already learned about stem cells indicates great potential,
which is an argument for moving ahead.
Opponents of embryonic stem cell research claim that there is
still much to learn from adult stem cells and therefore we should
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focus our efforts there. It is true that adult stem cells may hold po-
tential, and I fully support researching the possibilities of adult
stem cells. But evidence tells us that the potential of adult stem
cells may be limited because they are already more specialized
than other types of stem cells. We should indeed move forward
with research on adult stem cell lines, but this is no argument
against pursuing study of other types of stem cells with even more
potential.
The third issue we will discuss today is the safety of women who
donate oocytes or eggs for stem cell research. Egg donation relates
to a specific type of research called somatic cell nucleic transfer
[SCNT]. This technique involves removing the nucleus of an
unfertilized egg and replacing it with the nucleus of an adult cell.
SCNT has two benefits compared to stem cell research on em-
bryos from a fertility clinic. First, the possible outcome of this re-
search is the production of tissues that are genetic match to the pa-
tient, reducing the risk of rejection such as that we have often seen
with organ recipients.
Second, the technique holds great potential for studying genetic
and other diseases because scientists could potentially develop cells
using nuclei from people who have the disease. This would not gen-
erally be possible using embryos donated from fertility clinics be-
cause researchers cannot select the genes for such cells.
Witnesses today will discuss their concerns about the safety of
the women who donate eggs for this research. Some of these con-
cerns are legitimate. The drugs and techniques used are identical
to those used by women undergoing fertility treatments, but they
are not without risk. And I believe that we need to carefully exam-
ine research and monitor safety.
I also agree that we need to think carefully about how egg donors
for research should be compensated. We must respect the contribu-
tion that these women make, and we must ensure that they partici-
pate voluntarily. As with any new field of research, the safety and
ethics of human participants are paramount.
What we must not do, however, is become paralyzed into inac-
tion. Stem cell research, including research using embryonic cells,
may help cure diseases that cause untold suffering to millions of
Americans and hundreds of millions more around the world. With
strict scientific and ethical oversight, embryonic stem cell research,
including SCNT, should be supported with Federal funds.
Thank you, Mr. Chairman.
[the prepared statement of Hon. Henry A. Waxman follows:]
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Mr. SOUDER. Congresswoman Schmidt.
Ms. SCHMIDT. Thank you. Thank you, Chairman Souder, for
holding this important hearing on the abuse in human cloning and
embryonic stem cell research.
As a strong supporter of reasonable science, true women’s health,
and the culture of life, this topic is very dear to my heart. I com-
mend you, Chairman Souder, for bringing these panels of experts
together to shed light on the dangerous practices that some re-
searchers are willing to use to advance their agenda. They, with
the help of the media, have unfairly raised the hopes of many
Americans, who have been led to falsely believe that embryonic
stem cell cures are possible in the near future.
While scientists were touting Hwang’s research as
groundbreaking and necessary for the medical miracles around the
corner, Hwang was actually falsifying data and possibly exploiting
women for their eggs. How many of these promises were ill-found-
ed?
While it now appears that no scientist has effectively created
stem cell lines using cloned embryos, adult stem cell treatments
march ahead showing great promise for numerous diseases. The
facts have shown that cord blood stem cells and adult stem cells
are making great advances in curing diseases today, while clinical
trials in embryonic stem cells are still years away.
In the light of this fraud and abuse, and the fact that embryonic
stem cell research is just not producing the results that were prom-
ised, I am proud to have co-sponsored H.R. 596, the Stem Cell
Therapeutic and Research Act of 2005, or the cord blood bill, and
H.R. 1359, the Cloning Prohibition Act.
Again, Mr. Chairman, I applaud your leadership on these issues,
and I look forward to learning more about them to working with
you for a rightful resolution.
Mr. SOUDER. Thank you.
Ms. Norton.
Ms. NORTON. Thank you very much, Mr. Chairman. I want to
thank you for focusing the subcommittee on an unusually thor-
ough-going example of the worst kind of scientific fraud because
what we have in the Hwang—I hesitate to call it South Korean ex-
ample because I would hate to think that is characteristic of the
science of our friends in South Korea, but it is certainly an example
the likes of which I don’t think anyone has ever seen before, a mas-
sive scientific fraud at every level, fraud that was so good, as it
were, if you would forgive the use of the phrase, that even other
scientific researchers around the world were fooled by it.
It is a kind of case study in what can happen when nobody is
watching very closely, and when scientific research at the cutting
edge goes totally and absolutely unregulated. It was very trouble-
some to see and to count the violations and to see that they ranged
from what scientists were doing to violations of individual human
rights acknowledged to be important and necessary to the world.
So I welcome laying this matter out in detail, although I must
say I was fascinated with what my good friends on the other side
focused on. I mean, you would have thought this was not the Con-
gress of the United States that could do something about the issue
that we are describing today.
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I mean, we are not a television program. Any reasonably literate
person or anybody who looks at television has been scandalized by
what happened in South Korea. I am pleased we are focusing on
this matter not because of any evidence I know of that anything
close to it is happening here, but because I have no reason to be-
lieve that what happened in South Korea could not or would not
happen here, at least to some degree. And I believe it is urgent to
move this Congress and this subcommittee from what we cannot do
anything about to what we can and must do something about.
This is a national issue, my friends. On a national scientific issue
of this kind, the burden is on the Federal Government, first and
foremost, to offer leadership and guidance. So if you are really con-
cerned about South Korea, this is the time to focus on remedy, if
ever there was.
This much is clear: We cannot legislate against science any more
than we can legislate against the weather. But we can ourselves
enact reasonable measures in order to make sure that Congress
does not—that science does not march ahead in violation of every
ethical measure that both science universally has accepted and
that are a matter of documented international human rights.
Instead, very frankly, I must say that time after time, I see the
Congress trying to stop science. I am embarrassed by the congres-
sional approach to the march of science. It is as if we were still in
the 19th century. Science is marching ahead, and it requires deeply
analytical, very deep thinking about how to harness science when
we know good and well it is marching.
And how do we know it is marching ahead? Well, next door you
have heard my good colleague from Maryland talk about what is
happening in that State. A Republican Governor, Governor Robert
Ehrlich, has proposed spending $20 million on stem cell research
in the coming year. That is happening all over the United States.
The States are joining the advanced countries of the world, march-
ing ahead to make use of embryonic cell research.
I can only hope that in the countries of our allies, the national
legislatures have been more enlightened than to sit by and describe
the problem, while parts of their countries march ahead and do
whatever they want to do. We could affect how Maryland, how
California, and how every other State in the United States goes
about this work because we are the Federal Government.
I have every confidence that Mr. Cummings’ colleagues in Mary-
land are going to take up the slack and do the appropriate guid-
ance. I don’t think there is a State in the Union that would allow
this work to go forward without redoubling their efforts in every
way to make sure that what happened in South Korea cannot hap-
pen here.
So I don’t need to add to the disagreement on the ban on embry-
onic research. You are not going to change peoples’ minds on that.
You haven’t done it in the States, some of which are governed by
Republicans.
But I want to ask this question: Unbelievably, Mr. Chairman, no
bill has passed this Congress outlawing, banning, even human
cloning. Can we agree on that? Can we get everybody to raise their
hands on that? Isn’t there any part of this issue where we would
be prepared to meet our obligations, instead of going over and over
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again the polarizing issue of shall we ban what we can’t ban and
what our States are telling us we can’t ban because we are going
ahead and doing it.
So I believe that this hearing is important because perhaps it
could lead to more than beating our chests against the obvious.
There is no disagreement in the United States of America or
among anybody in this Congress that what happened in South
Korea should not happen here.
Hearings are for remedies. I will be interested in whether any of
the witnesses today are prepared to help this Congress move for-
ward on urgently needed remedies. And I Tim Howard, Mr. Chair-
man.
Mr. SOUDER. Ms. Foxx.
Ms. FOXX. Thank you, Mr. Chairman. I want to tell you how
pleased I am that you are having the hearing today.
I might get the reputation around here for being the person who
always brings up the issue of language and how important it is to
us. But I hear a lot of very inflammatory terms being used about
banning future stem cell research, and legislating against science,
and that we are not doing the kinds of things that we should be
doing.
We have not at all banned—talked about banning stem cell re-
search in the Congress. We have encouraged stem cell research,
adult stem cell research. I am really curious about the word ‘‘thera-
peutic cloning’’ being used. I don’t know how the destruction of
human life could ever be called therapeutic.
I think that what you are doing here today is calling attention
to what I think is a microcosm of the fraud that has been per-
petrated in relation to embryonic stem cell research itself. I think
focusing on what has happened in Korea and the fraud that hap-
pened there can, I think, enlighten people about this issue of em-
bryonic stem cell research and the negative things about that. So
I think we can change peoples’ minds. I think we can enlighten
people. And I think we can do it in a way that is respectful of
human life and not destructive of human life.
So I applaud you for holding the hearing, and look forward to our
shedding some light on this issue that is the truth, rather than let-
ting something like this continue to be a fraud. We have allowed—
unfortunately, people in very sad circumstances think that by the
use of embryonic stem cell research, we are going to have a cure
right around the corner. And we know that it has brought no cures,
whereas adult stem cell research has.
So thank you for doing this, and thank you for calling attention
to the issue.
Mr. SOUDER. Thank you. I ask unanimous consent that all Mem-
bers have 5 legislative days to submit written statements and ques-
tions for the hearing record, and that any answers to written ques-
tions provided by the witnesses also be included in the record.
Without objection, it is so ordered.
I also ask unanimous consent that all exhibits, documents, and
other materials referred to by the Members and the witnesses may
be included in the hearing record, and that all Members be per-
mitted to revise and extend their remarks.
Without objection, it is so ordered.
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Before swearing in our first panel, I feel compelled to tell all of
our witnesses to remember: This is an oversight committee, not a
legislative committee. We only have legislative jurisdiction over
narcotics. We do oversight and legislation on narcotics.
On the Department of Health and Human Services, we do not
write the bills. We are here to talk about the past. What the ques-
tion is in front of us is what happened there and whether in fact
they are inherent to the process, or whether in fact controls can be
made to regulate this.
It is a legitimate debate, but it is not about where we are headed
legislatively. First, we are here to analyze the past, analyze what
has happened, analyze what the different agencies are doing and
what the potentials are, that then Energy & Commerce and the
Health Committee and others would look at legislatively. I think
there was some confusion on the panel as to the role of our hearing
and what our committee does. And I think it is important to clarify
that.
Now, as you know, it is the practice of this committee to swear
in their witnesses. Our first panel is Dr. James Battey, Chair of
the NIH Stem Cell Task Force and Director of the National Insti-
tute for Deafness and Other Communication Disorders; Mr. Ber-
nard Schwetz, Director of the Office for Human Research Protec-
tions; and Chris Pascal, Director of the Office of Research Integrity.
Would you each stand and raise your right hand?
[Witnesses sworn.]
Mr. SOUDER. Let the record show that each of the witnesses re-
sponded in the affirmative.
We appreciate that you have joined us, and we will start with
Dr. Battey.
STATEMENTS OF JAMES F. BATTEY, JR., M.D., Ph.D., CHAIR,
NIH STEM CELL TASK FORCE, DIRECTOR, NATIONAL INSTI-
TUTE ON DEAFNESS AND OTHER COMMUNICATION DIS-
ORDERS, NATIONAL INSTITUTES OF HEALTH, U.S. DEPART-
MENT OF HEALTH AND HUMAN SERVICES; BERNARD
SCHWETZ, D.V.M, Ph.D., DIRECTOR, OFFICE FOR HUMAN RE-
SEARCH PROTECTIONS, U.S. DEPARTMENT OF HEALTH AND
HUMAN SERVICES; AND CHRIS B. PASCAL, DIRECTOR, OF-
FICE OF RESEARCH INTEGRITY, U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
STATEMENT OF JAMES F. BATTEY, JR.
Dr. BATTEY. Good afternoon, Chairman Souder and distinguished
members of the subcommittee. I am pleased to be joined here by
my two other colleagues from the Department of Health and
Human Services. And I appear before you today in my joint roles
as a scientist and Chair of the NIH Stem Cell Task Force to dis-
cuss the recent events concerning stem cell research fraud that is
reported to have occurred in South Korea.
As you know, a review and analysis by the Seoul National Uni-
versity Investigation Committee concluded that human embryonic
stem cell lines were not derived from embryos created by somatic
cell nuclear transfer, as claimed, that fabricated data was used in
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publications, and that there had been ethical violations in the do-
nation of human oocytes used in these experiments.
In 2004, Dr. Woo Suk Hwang and collaborators published an ar-
ticle in the journal Science claiming that they had derived a stable
human embryonic stem cell line, which they referred to as NIGHT–
1, from an embryo generated by somatic cell nuclear transfer. That
is a process, as Mr. Waxman described, where the nucleus is re-
moved from a human oocyte and replaced by the nucleus from a
somatic cell.
Subsequent investigation by the Seoul National University inves-
tigation committee revealed that this claim was not supported by
rigorous DNA testing. In addition, the investigation revealed that
the photographs allegedly taken of the NT–1 cell line were in fact
photographs of an existing stem cell line not derived from an em-
bryo created by SCNT, but instead derived from an embryo pro-
duced by in vitro fertilization.
In 2005, Dr. Hwang and collaborators published a second article
in Science, where they claimed to have made the process or deriv-
ing human embryonic stem cell lines from embryos created by
SCNT much more effort than was reported in the 2004 publication,
where several hundred oocytes were reported to be needed to create
a single stem cell line, which we now know was not created in the
way they described.
In this paper, the authors claimed to have developed an im-
proved protocol for deriving patient-specific embryonic stem cells
from embryos created through SCNT. They reported the creation of
11 human embryonic stem cell lines from 185 embryos created by
SCNT, many of which involved nuclei from cells derived from indi-
viduals with debilitating diseases such as spinal cord injury, juve-
nile diabetes, or congenital inherited deficiencies of the immune
system.
Subsequent review by Seoul National University led the inves-
tigation committee to conclude that the data presented in this 2005
paper was based on only two human embryonic stem cell lines, nei-
ther of which was derived from an embryo created by SCNT. They
concluded that no disease-specific human embryonic stem cell lines
derived from SCNT embryos are represented in this publication,
nor is there any factual basis for believing the Koreans ever suc-
cessfully created any such lines.
While the events in South Korea are deeply troubling to all of us
here and everyone in the scientific community, I think it is impor-
tant to point out that scientific fraud of this type is not common
at all, and is certainly not restricted to the area of stem cell re-
search. As one of your colleagues pointed out earlier, John Darcy
fabricated data in hundreds of publications in the area of cardi-
ology over a decade ago. That doesn’t mean that it was inappropri-
ate to continue doing work in the area of cardiology.
The scientific community must remain as vigilant as we can be
to ensure that the risk of scientific fraud is minimized. It is also
important to note that such fraud is sometimes revealed, often re-
vealed, when other reputable scientists cannot reproduce results
that are subsequently revealed to be fabricated, and the great ma-
jority of scientists around the world are deeply committed to rigor-
ous standards of proof and verification. The Rosetta Stone of
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science is reproducibility in another independent laboratory. And
this is where scientific fraud is typically uncovered.
The scientific enterprise absolutely depends on such standards.
And while the stem cell research fraud in South Korea is com-
pletely unacceptable, it does not reflect on the potential of human
embryonic stem cell research one way or the other. The vast major-
ity of my scientific colleagues are honest and hardworking in pur-
suing their research, which they deeply hope will ultimately benefit
the human condition.
I thank you very much for your time, and I will do the very best
I can to answer any questions that the subcommittee may have for
me.
[The prepared statement of Dr. Battey follows:]
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Mr. SOUDER. Thank you.
Dr. Schwetz.
STATEMENT OF BERNARD SCHWETZ
Dr. SCHWETZ. Mr. Chairman and distinguished members of the
subcommittee, I am Bernard Schwetz, the Director of the Office for
Human Research Protection. Thank you for inviting me here today
to discuss the Department of Health and Human Services [HHS],
Protection of Human Subjects regulations, particularly as they re-
late to human cloning and embryonic stem cell research.
These HHS regulations are designed to protect the rights and
welfare of all who participate in research studies that are con-
ducted or supported by HHS. They are based in large part on the
ethical principles for human subjects research identified in the Bel-
mont Report that was written by the congressionally mandated Na-
tional Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research in 1978.
The protection of human subjects in research studies is a priority
for HHS, and it is the mission of the Office for Human Research
Protections [OHRP], to support, strengthen, and provide leadership
to the Nation’s system for protecting volunteers in research that is
conducted or supported by HHS.
By signing an assurance of compliance with OHRP, an institu-
tion pledges to conduct its HHS-funded or supported research in
accordance with these regulations. In addition to assurances of
compliance, the HHS regulations also stipulate a number of other
requirements for which the institution and its institutional review
board [IRB], are responsible.
Primary among these is the need to determine if the risks to sub-
jects are reasonable in relation to anticipated benefits, if any, to
the subjects, and the importance of the knowledge that may rea-
sonably be expected to result. Some research studies offer individ-
ual studies the prospect of direct benefit, and others do not.
When research studies offer no prospect of direct benefit to re-
search subjects, IRBs must consider whether the potential benefits
to society justify the risks to the individual subjects. For these
studies, including some research involving human embryonic stem
cells, the expected benefits would occur often in the future, and
would only be of help to others.
Informed consent: At the heart of the human subject protection
system is the requirement relating to informed consent. The inves-
tigator must seek a potential subject’s informed consent according
to the requirements laid out in the regulations. The investigator’s
method for obtaining this consent must be approved by the IRB be-
fore it can be used.
In seeking informed consent, HHS regulations require that inves-
tigators do so only under circumstances that provide the prospec-
tive subject with sufficient opportunity to consider whether or not
to participate, and that minimizes the possibility of coercion or
undue influence.
As part of the consent process, the prospective research subject
must be given sufficient information about a research study to
make an informed decision about whether or not to participate in
the research. If the study does not offer the subjects the possibility
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of direct benefit, this must be clearly stated in the informed con-
sent process.
For example, if a research study that involves identifiable human
cell lines is not intended to offer donors with the prospect of direct
benefit, then prospective donor subjects would need to be informed
of this unless the requirement for the informed consent has been
waived by the IRB.
OHRP guidance on research involving stem cells: OHRP has pro-
vided guidance to help insure that investigators and IRBs under-
stood how the HHS regulations apply to research involving human
embryonic stem cells, germ cells, and the stem cell-derived test ar-
ticles. A copy of this guidance is included in my written statement
for your consideration.
In essence, this guidance indicates when such research does and
does not generally meet the HHS definition of human subjects re-
search. Under the HHS regulations, ‘‘human subject’’ means a liv-
ing individual about whom an investigator conducting research ob-
tains either data through intervention or interaction with an indi-
vidual, or identifiable private information.
OHRP considers that neither of these definitions is met with re-
search involving embryonic stem cells as long as the investigator
has not obtained data about an individual through a research
intervention or interaction, and cannot readily ascertain the iden-
tity of the individual from whom the human material was obtained.
In such cases, the study would not be considered human subject re-
search and the institution’s IRB would not be required to review
this type of research.
However, some research may use established human cell lines
where the donor or donors may be readily identified by investiga-
tors, or may involve the obtaining of data through research inter-
ventions or interactions with individuals. In these cases, the re-
search is considered to have involved human subjects, it would be
governed by the HHS regulations, and IRB review and approval
would be required for the research to proceed.
Finally, I would like to emphasize that the stem cell research
conducted at Seoul National University by Dr. Hwang which pro-
vided the impetus for this hearing was neither conducted nor sup-
ported by HHS. Quite apart from the issues of fraud and abuse,
such research could not have been conducted or supported by HHS
under Federal law in the United States.
Dr. Hwang’s research involved attempts to create new human
embryonic stem cell lines solely for research purposes through the
process of somatic cell nuclear transfer, sometimes called human
cloning. HHS is specifically prohibited by law from supporting re-
search in which a human embryo or embryos are destroyed, as well
as from supporting the creation of a human embryo or embryos for
research purposes. And that law defines ‘‘human embryo’’ to spe-
cifically include embryos created by cloning.
As it was not conducted or supported by HHS, and does not ap-
pear to have been conducted at an institution that voluntarily
agreed to comply with the HHS regulations for all human subjects
research conducted at the institution, Dr. Hwang’s research was
therefore not subject to any of the regulatory protections that I
have discussed throughout this statement.
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Thank you for your attention, and I would also be happy to an-
swer any of the questions you may have.
[The prepared statement of Dr. Schwetz follows:]
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Mr. SOUDER. Thank you.
Director Pascal. Did I say that correctly? Or Pascal? Thank you.
STATEMENT OF CHRIS B. PASCAL
Mr. PASCAL. Chairman Souder and distinguished members of the
subcommittee, I appreciate the opportunity to talk to you today
about research misconduct and the work of the Office of Research
Integrity in the Department of Health and Human Services.
ORI is charged with overseeing allegations of research mis-
conduct in biomedical and behavioral research supported by the
U.S. Public Health Service. ORI has over 10 years of experience in
reviewing misconduct allegations and making findings of research
misconduct.
PHS-supported research institutions and ORI make findings of
research misconduct when evidence demonstrates that fabrication,
falsification, or plagiarism has occurred in PHS-funded research.
ORI has made more than 160 findings of misconduct since 1992,
and has reviewed hundreds of additional allegations of misconduct
that did not result in misconduct findings.
In May 2005, HHS published a new, more comprehensive regula-
tion governing research misconduct investigations entitled, ‘‘Public
Health Service Policies on Research Misconduct,’’ codified at 42
CFR part 93, which can be found on the ORI Web site. This new
regulation replaces the previous regulation from 1989 for dealing
and reporting research misconduct.
ORI is aware of the controversy regarding Dr. Hwang’s human
stem cell research project at Seoul National University and the
findings of fraud by the Seoul National University investigation
committee. However, based on current information available to
ORI, ORI has no jurisdiction in this matter since the research was
not supported by PHS funds, and ORI does not have jurisdiction
over non-PHS-supported research.
Had the actions been under the purview of HHS, ORI has a staff
of scientists and additional consultants who have developed exten-
sive knowledge and exploits in overseeing and assessing allegations
of research misconduct, primarily through evaluating investiga-
tions conducted by the PHS-funded research institution.
By law, direct investigations are usually initiated by the research
institutions that receive allegations of research misconduct. These
allegations are generally made by members of the grantee institu-
tion who are part of the particular laboratory or department con-
ducting the research. And I might add that ORI considers these in-
dividuals to be heroes in coming forward with allegations of re-
search fraud because without them, it would continue and grow.
And those individuals take great risk to come forward.
One or more members of the team may suspect misconduct and
then report it to the grantee institution directly. Sometimes the in-
vestigator suspecting fraud will report to ORI, and then ORI will
refer the matter to the appropriate grantee institution for review.
Grantee institutions are required by the HHS regulations to report
allegations to ORI when they reach the formal stage of investiga-
tion of the process, and when admissions of misconduct are made
by the accused scientist.
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In conducting the investigation, the institution must promptly se-
cure the research records—without access to the research records
and to the original data, it is very difficult to solve these cases—
and other relevant documents in order to have a sound basis to
identify and evaluate any evidence of research misconduct.
When an institution has completed its investigation, it must sub-
mit a written report to ORI. ORI will then engage in a thorough
oversight review of the report and, depending on the quality and
thoroughness of the investigation, may accept the institutions re-
port and find either misconduct or no misconduct based on the in-
stitution’s findings.
If ORI believes further investigation is required, we may request
and review the grantee institution’s entire investigation record, in-
cluding the research data, copies of interviews or tapes of inter-
views, and other relevant documents. When the analysis is com-
pleted, ORI may find no misconduct and close the case, or propose
findings, PHS findings of research misconduct.
ORI findings of no misconduct, as well as open cases that are
under review, are considered confidential, both by the ORI regula-
tion and other Federal law, and ORI does not discuss these cases
publicly. When HHS makes a finding of misconduct, however, it
formally announces the finding, which is then published in the
Federal Register, summarized on the ORI Web site and in our
newsletter, and the finding is listed in the NIH Guide for Grants
and Contracts. In ORI’s view, it is important to make these find-
ings public. Otherwise, scientists can move around to other institu-
tions and commit fraud again if it is not public information.
HHS takes findings of research misconduct seriously and takes
appropriate action. Findings of research misconduct typically result
in remedial HHS administrative actions that may include debar-
ment or suspension from PHS-funded research, which means they
cannot come back to the Public Health Service and get new funding
for a period of time. And in very serious cases, they could be pre-
cluded from doing so for life.
ORI also strives to correct the research record that may have
been corrupted by fraudulent studies. As you heard earlier today,
Science withdrew two articles that were published because of the
fraud, and we think that is very important to making sure that the
scientific record is accurate and honest for other scientists and the
public to rely upon.
In those research misconduct cases that result in criminal fraud
charges, which has happened a couple of times, and civil proceed-
ings of false claims, ORI works collaboratively with the Depart-
ment of Justice and other Federal law enforcement agencies, in-
cluding the HHS Office of the Inspector General. Accused scientists
who wish to contest findings of research misconduct are offered a
due process administrative hearing to defend themselves.
In order to promote research integrity and responsible research
practices, ORI has an active education program. We collaborate
with the scientific community, and we provide resources to institu-
tions to develop their own educational products.
ORI believes that its educational programs and collaborations
with the research community can help prevent research mis-
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conduct. It will not ever eliminate it just because of the nature of
the human condition.
For example, ORI has a collaboration with the Association of
American Medical Colleges to fund scientific and academic societies
to hold workshops and conferences on research integrity issues, or
develop guidelines or educational programs describing appropriate
normative standards for conducting and reporting research.
ORI has a collaboration with the Council of Graduate Schools to
fund pilot projects at 10 institutions to provide formal training to
graduate students in the responsible conduct of research. ORI has
published a booklet on responsible conduct of research that has
been translated into Chinese and Japanese, as well as in English.
Finally, ORI has an active program of evaluation and research
studies, partly in collaboration with the National Institutes of
Health within HHS, to determine what scientific practices are
working well and to learn what practices can be improved. It is im-
portant to study the science of science itself in order to improve
how you conduct research.
Although any individual case of research misconduct can have se-
rious consequences for biomedical research, it is ORI’s experience
that the great majority of scientists are dedicated to conducting re-
search in a responsible and professional manner, and are commit-
ted to producing research results that will benefit all Americans
and healthcare consumers around the world.
Thank you for the opportunity to discuss ORI’s work, and I
would be pleased to answer any questions you have.
[The prepared statement of Mr. Pascal follows:]
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Mr. SOUDER. Let me start with the questioning. And first, if we
are going to have any kind of reasonable discussion, let’s cut out
this cardiologist stuff and so on. There is a major difference be-
tween the exceptions in fraud that we see in the scientific commu-
nity in fields of research where we have had research for decades
and decades, and fraud in the sole big case touted in journals and
touted by all sorts of researchers in a field that has no history of
such research, and the question of whether the fraud involved was
endemic to the process. Don’t treat us like little children and try
to BS us. It is not going to work.
Now, one of the things that Mr. Waxman, Mr. Cummings, and
I have had a question about baseball and steroids is whether or not
you can trust an institution to patrol itself when they have a finan-
cial stake in the matter that is being investigated.
And Mr. Pascal, you went through this detail, but you said the
first, basic, where you get your information whether there is fraud
is whether the grantee discovers there is fraud, who clearly has a
conflict of interest. Could you elaborate on this and how you
would—how we find out, if the institution chooses to cover up? Be-
cause South Korea had tougher laws than we have in the United
States, and they weren’t followed.
Mr. PASCAL. Well, it is true that an institution can have a natu-
ral preference for not finding research misconduct. It can lead to
embarrassment, it may lose—loss of funds from NIH or whoever
the funding source is, or whatever.
But based on ORI’s many years of experiences with institutions,
we think most of them want to do a good job in finding out what
actually happened, and make findings when it is appropriate. In
fact, some institutions make findings of research misconduct that
ORI does not pursue because we don’t think the evidence is sub-
stantial enough to support a finding that we could uphold in an ad-
ministrative hearing.
Also, part of this is in the structure of the regulatory process.
Our new regulation has followed the policy established by the Of-
fice of Science and Technology Policy which was adopted in 2000,
which states that research institutions bear primary responsibility
for prevention and detection of research misconduct, and for the in-
quiry and investigation and adjudication of research misconduct al-
leged to have occurred in association with the institution.
There are also a number of checks and balances in the ORI regu-
lation. ORI has oversight review over the institution’s findings. The
institution sometimes will make minimal findings or weak findings,
and ORI will come in and do additional analysis and investigation
with its scientists, and we make additional findings.
There is a regulatory requirement that the institution must uti-
lize experts in the relative scientific field, and must ensure objec-
tivity in the investigation. That is a regulatory——
Mr. SOUDER. Let me ask a followup question and we will submit
your full answer for the record.
Mr. PASCAL. OK.
Mr. SOUDER. Because that is basically the procedure that Korea
had.
In ORI, you have given a major grant to University of Pittsburgh
researcher Gerald Schatten, who is the co-author of these studies,
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who withdrew after the fraud became public, but who was co-au-
thor. And I am going to have some detailed questions that we sub-
mitted before and we are trying to get the answers to.
But given that he cited this Korean research multiple times in
his grant application, are you in the process of reviewing that
grant? And do you have a process—because in effect, what you
were just giving me is a whole process that, if the review was
weak, if you had questions about it, then you could step in. Are you
reviewing this grant?
Mr. PASCAL. Due to ORI confidentiality constraints, we cannot
admit nor deny any specific——
Mr. SOUDER. OK. Let me re-ask. Do you have the authority to
review this grant based on the information that came out that he
had been a co-author of the fraudulent study in Korea?
Mr. PASCAL. If there is a matter that involves PHS funds and al-
leged research misconduct, yes. ORI would have authority to re-
view the results of the investigation by the institution.
Mr. SOUDER. And Dr. Battey, I am going to read a number of
questions here. You have been—we sent these over 2 years ago.
Your response to some of the questions was—not these particular
questions, but you responded slowly to some of the others. But we
are trying to make a policy. And I am going to read a couple of
these. If you can kind of give a general feeling, and then submit
back in the record regarding Pittsburgh researcher Schatten’s ques-
tion.
One is, how much money was spent on human embryonic stem
cell research in 2005, and how much of that went to University of
Pittsburgh researcher Gerald Schatten?
Also, is his research on the Bush-approved stem lines as well as
on primate embryos, and could you separate that funding for us?
Also, of his $16.1 million, how does this compare to other people
who have embryonic stem cell grants? If you could give us his rank
in terms of grants for the research on monkeys and approved stem
lines, and how many grants he has been awarded. And is he your
top single grantee? Because his grant makes reference several
times to this Korean research, which he was co-author of till he
withdrew after the fraud became public.
And also, will you give us the 2005 figures for ESCR grant
awards? How many grants, total dollar amount, smallest grant
award, and largest grant award? Because quite frankly, and your
agency is doing oversight, this is just basic data, and it shouldn’t
take 2 years to get to this oversight committee to get basic data.
Now, if you don’t have it today, although we did submit these in
advance.
Dr. BATTEY. Let me do the best I can to answer your questions
immediately.
In fiscal year 2005, NIH supported about $40 million in research
involving human embryonic stem cells. In fiscal year 2005, Dr.
Schatten’s NIH-supported research involving human embryonic
stem cells was approximately $1.1 million.
Getting to your issue about size of grants, Dr. Schatten is not the
champion in terms of garnering NIH support for human embryonic
stem cell research. Larger awards have been made, and in fact, an
award of a little over $4 million was made to WiCell, which is a
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biotechnology firm associated with the University of Wisconsin, to
form the National Stem Cell Bank, which is an effort to make the
stem cell lines that are eligible for Federal funding more readily
available to the research community.
In fiscal year 2005, NIH supported 154 individual research
projects involving human embryonic stem cells at the total amount
of about $40 million. Of these, the smallest grant was $2,000
awarded to NGRI Intramural Scientists to conduct genome insta-
bility in cancer development research. The largest human embry-
onic stem cell project was the $4.2 million that I mentioned earlier
awarded to the WiCell Research Institute.
Mr. SOUDER. Thank you very much. That was helpful. Can you
submit a full list of the grants for the record?
Dr. BATTEY. The full list of the 154 individual research projects?
Yes.
Mr. SOUDER. In 2005?
Dr. BATTEY. Yes.
Mr. SOUDER. OK. Thank you very much.
Yield to Mr. Cummings.
Mr. CUMMINGS. Thank you very much.
Dr. Battey, I think it was you that said that one of the best ways
to discover fraud in these instances is when you have to duplicate
the research in another lab. Is that correct?
Dr. BATTEY. Yes. If I can elaborate on that for just a moment.
Mr. CUMMINGS. Please do.
Dr. BATTEY. When a major scientific breakthrough takes place,
it generally has implications for research going on in a number of
other independent laboratories. And one of the first things they will
try to do to take the next step and build on that research is to take
the protocol that was reported in the published literature to have
given a specific result and reproduce that result.
Now, when multiple laboratories around the world or in the
United States cannot reproduce a major scientific finding, it rapidly
falls into disrepute.
Mr. CUMMINGS. Now, you stated in your testimony that while the
stem cell research fraud in South Korea is unacceptable, it doesn’t
reflect on the potential of human embryonic stem cell research one
way or the other. Is that what you said?
Dr. BATTEY. I am saying that the arguments for or against doing
human embryonic stem cell research are not directly implicated by
the—or directly influenced by the fraud that everybody agrees was
inappropriate that took place in South Korea.
Mr. CUMMINGS. You know, the thing that has—I think you lis-
tened to the opening statements, and you heard Ms. Norton. And
I think one of the major concerns here is, do you—I mean, are you
a scientist?
Dr. BATTEY. I am reported to be a scientist, yes.
Mr. CUMMINGS. OK. Well, I will take your word for it.
Dr. BATTEY. My mother thinks I am a scientist.
Mr. CUMMINGS. I am sorry. Say that again?
Dr. BATTEY. My mother thinks I am a scientist.
Mr. CUMMINGS. Your mother?
Dr. BATTEY. Yeah.
Mr. CUMMINGS. OK. That is good. [Laughter.]
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Dr. BATTEY. She also thinks I am a doctor.
Mr. CUMMINGS. I guess the question becomes—I think at least
two of you, and I know Mr. Waxman, referred to it, and others—
this whole thing of fraud and whether the fraud in an area like
this should then cause us not to go into that area. And then the
chairman got very upset when we talked about—you all talked
about the cardiology piece.
But I guess the point is that you can have these problems. You
are going to have problems as long as you have human beings
doing things. The question becomes, do you stop going in the direc-
tion because of that research. Is that what you all are saying?
Dr. BATTEY. My comment was that there is an enormous poten-
tial to improve the human condition through research that involves
all types of stem cells. And it is my belief, and the belief of the Na-
tional Institutes of Health, that we need to move forward and ex-
plore all avenues that are reasonable and ethically sound that have
the potential to alleviate human suffering.
Mr. CUMMINGS. And when you see instances like California and
Maryland moving toward funding this research, how does that af-
fect the people in you all’s shops? In other words, if you see States
now moving toward that and you are, I guess, kind of standing on
the sideline and watching, does that create concern for you all at
all?
Dr. BATTEY. My job as the Chair of the NIH Stem Cell Task
Force, which is a role that I was asked to assume by the NIH Di-
rector, Dr. Zerhouni, in the summer of 2002, is to try to find areas
within the President’s policy where we can accelerate the pace of
research using stem cells.
And I think it is fair to say that there has been very significant
progress made by support provided by the National Institutes of
Health. As I mentioned, in the last fiscal year we have 154 re-
search projects. We invested $40 million. And much has been
learned about the fundamental events that drive cells to become
specialized adult cell types.
This is the information that will ultimately allow us to poten-
tially generate cells for cell replacement third party in the labora-
tory; to potential mobilize endogenous populations of stem cells
within patients to become these interesting cell types; or, ulti-
mately, to understand the molecular mechanisms that determine
this magical process of nuclear reprogramming whereby an adult
nucleus in a specialized cell can turn back the clock and become
a pluripotent cell nucleus, and in so doing, allow us the opportunity
to generate pluripotent cells without the destruction of human em-
bryos.
Mr. CUMMINGS. We have a tough time situation, but I have to
ask you this one last question. You know, so you—based upon what
you just said and your testimony, you don’t see this area of re-
search as some pie in the sky. And it has been implied that some
of this research is just giving people false hope. You don’t see that
based upon your knowledge and expertise? Do you understand the
question?
Dr. BATTEY. I understand the question very well, I believe. I will
say freely that the comments that have been made about therapies
using adult stem cells and the therapies using embryonic stem cells
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at this time are 100 percent true. There are no therapies using
human embryonic stem cell lines at the current point in time.
Adult stem cells, in particular hematopoietic stem cells, stem
cells of the blood-forming organ, the bone marrow, have been part
of the research landscape for nearly 31⁄2 decades. Human embry-
onic stem cells first became available to the research community in
1998, when James Thompson published his landscape paper.
I think it is premature at this point in time to evaluate exactly
what type of stem cell and in what way knowledge gleaned from
studying that type of stem cell in 10, 20, or 30 years is going to
inform the medicine of the future and empower the next generation
of physicians.
Mr. CUMMINGS. And I imagine if we had taken that position in
a lot of our science, we wouldn’t be where we are today in various
areas of science.
Dr. BATTEY. It is unfortunate, but the progress of science is usu-
ally incremental. And we make slow steps forward, and it takes
many, many of those slow steps over a long period of time, before
we have even done the safety and efficacy testing in animal models
that poise us to do the first experiments that involve human pa-
tients.
And I am delighted to be joined here by my colleagues from Of-
fice of Human Research Protection, who see to it that we do these
studies in people in a responsible fashion. You know, we are abso-
lutely bound to do that, as human beings and as physicians.
Mr. CUMMINGS. Thank you very much.
Mr. SOUDER. I really need to hold to the 5-minute rule because
we have a lot of Members, and we are trying to reach a 5 p.m.
deadline, and we have six witnesses on the second panel.
Ms. Foxx.
Ms. FOXX. Thank you very much.
I want to ask Dr. Battey: Did SCNT create Dolly the sheep?
Dr. BATTEY. Dolly the sheep was created by somatic cell nuclear
transfer. That was in fact the time that we learned that an adult
cell nucleus could be reprogrammed. That was the first demonstra-
tion that I am aware of in a mammal that was possible, although
such experiments had been done in amphibians for decades.
Ms. FOXX. Then what is the difference between somatic cell nu-
clear transfer and cloning?
Dr. BATTEY. Somatic cell nuclear transfer is the process whereby
the nucleus is removed from an oocyte and replaced by the nucleus
from a somatic cell, a body cell. That is why it is called somatic cell
nuclear transfer.
When this procedure is done with the goal of creating an embry-
onic stem cell line that is genetically matched to an individual or
has a specific genetic background, that term that is used for that
is therapeutic cloning. When it is done with the intent of creating
a new life through—all the way through gestation and having, in
this case, a baby sheep born, in the case of Dolly, that is reproduc-
tive cloning.
And, you know, the nomenclature—you mentioned that language
can be very tricky. And the whole word ‘‘cloning’’ is a word that is
a tricky word because it is used in many different ways. In my lab-
oratory, we talk about cloning a cell line, which means basically
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taking a culture of cells and growing up a new culture from a sin-
gle cell.
We talk about cloning a recombinant DNA molecule, where we
take a single recombinant DNA molecule and make 10 to the 8 cop-
ies of that molecule. And then here we talk about therapeutic
cloning and reproductive cloning. And while they employ similar
technologies at the beginning, they have different end points.
Ms. FOXX. Well, I am curious about the phrase that you use,
‘‘ethically sound.’’ I wonder whose definition of ethically sound it is.
And I will tell you what went through my mind when you said
that, and I want to be very careful how I say this.
I heard a presentation a couple of weeks ago by a physician, and
he raised the issue of the Tuskegee experiments that were done.
If there is anybody here who doesn’t know those, those were experi-
ments done on African American men in Alabama, I believe, or—
I am not sure what State it was in, 40 years ago, 40 or 50 years
ago, where they were injected with syphilis, I believe, and then
studied for it.
I wonder if those people said those studies were ethically sound.
And would you feel that those were ethically sound studies?
Dr. BATTEY. No. I would not feel they are ethically sound. And
they led, in fact, to the creation of human subjects protection rules
as we know them today.
Ms. FOXX. OK. Then how would you define ethically sound if, in
the process of doing embryonic stem cell research, you are destroy-
ing human life? How do you define ethically sound?
Dr. BATTEY. That is the subject of a national debate at this time.
And there are many different opinions on that subject that cut to
the very heart of when people believe that life begins. That is a
subject where the major religions of the world are divided. And it
will be a subject that I predict will be a contentious subject that
will need to be debated for the foreseeable future.
Ms. FOXX. Mr. Chairman, that is the last question I had. But I
would really like to go back to some of the testimony that might
have been given around the Tuskegee experiments, and I will have
a feeling that a lot of the scientists who were engaged in those
used the very same language that you use.
Mr. SOUDER. Mr. Waxman.
Mr. WAXMAN. The Tuskegee experiments were reprehensible.
They involved human subjects who were not informed of the nature
of the experiments. As I understand it, they never were reviewed
by any outside agency. And you indicated, Dr. Battey, that is why
the whole protections for human subjects has been created, so that
an institutional review board has to approve any kind of experi-
ment to be sure that it is ethical and meets ethical standards. Is
that correct?
Dr. BATTEY. That is correct.
Mr. WAXMAN. Now, a lot of people worry that embryonic stem
cell research is going to be conducted. It is going to be conducted
by private companies.
If embryonic stem cell research is conducted by the Government,
is there a greater chance that ethical standards will be met, that
there are going to be—there will be greater scrutiny of all the pro-
cedures that go into that research?
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Dr. BATTEY. I think it is fair to say that there will be the same
scrutiny that we have applied to other areas of biomedical re-
search, with doubling scrutiny because of the respect that one has
to have for the sensitive area of research where there is an enor-
mous divide in our country.
Mr. WAXMAN. Well, the American Society for Cell Biology empha-
sized the importance of public funding. And they at one point said
that without Federal funding, the Nation’s top academic research-
ers at universities, medical schools, and teaching hospitals cannot
join in the search for cures, which means slower progress, and that
the Government oversight will ensure that research complies with
ethical guidelines.
Do you agree with that statement, that last point, and how does
it guarantee or ensure that research complies with ethical guide-
lines?
Dr. BATTEY. We can insist that before Federal funds are ex-
pended, that proper oversight has taken place. And that in fact is
done with all the research that involves human subjects, where the
experiment must be reviewed by an institutional review board in
the institution in question before such an experiment goes forward.
Mr. WAXMAN. In your view, does the Korean scandal establish or
suggest that the field of embryonic stem cell research is unique in
being susceptible to scientific fraud and/or patient exploitation?
Dr. BATTEY. Unfortunately, I am afraid that scientific fraud has
been found in many areas of science, as I mentioned earlier. It is
rare, but it happens in many different areas. And scientists need
to be vigilant to try to prevent it.
But I would emphasize that it is my sincere belief in my 23 years
of experience as a scientist has taught me that the overwhelming
majority of individuals engaged in biomedical research are sincere,
hardworking, and would like nothing better than to see what they
do in their laboratories lead to better cures and better health of the
Nation.
Mr. WAXMAN. Should women be allowed to donate eggs for purely
research purposes under any condition? And if so, what should
those conditions be? Maybe you want to——
Dr. BATTEY. I think that might be a better question for Mr.
Schwetz to try to answer, if he would like to, or I will answer to
the best of my ability if he would prefer.
Mr. SCHWETZ. All we can say is that if in fact there is going to
be research that involved eggs from donors, and this is research
that is funded by HHS and doesn’t involve the cell lines—it doesn’t
get outside of the cell lines that are acceptable for HHS-funded re-
search, then all we can say is that we have a network in place
through the institutional review board system that determines that
these protocols must be reviewed, and they need to meet the stand-
ards that are set in our regulation.
Mr. WAXMAN. Well, what if we changed the ban on this research
through NIH and broadened it to further investigations using em-
bryonic stem cells, does a—exploitation of women is a major and
disturbing theme in the story of the Korean scandal. Would this be
something that we could make sure is done appropriately, if a
woman wishes to participate in donating an egg for research be-
yond stem cells that are available now?
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Mr. SCHWETZ. It is hard to know what is going to come up in the
future. But based on what we know today, these—we are faced—
this is an enterprise that is faced with a number of risks in re-
search, and the possibility that there would be a problem with har-
vesting eggs from females is one of a number of risks that would
be handled by the institutional review board system on a regular
basis.
So I don’t think there are limitations in the regulations that
would suggest we shouldn’t go into this kind of research because
we don’t know how to handle it.
Mr. WAXMAN. We don’t know how to handle it until it is re-
viewed? Until some proposal is reviewed?
Mr. SCHWETZ. That is correct.
Mr. WAXMAN. OK. Thank you. Thank you, Mr. Chairman.
Mr. SOUDER. I have a feeling that though Mr. Waxman and I
may disagree fundamentally on where life begins and in embryonic
research, if this were to go forward with congressional standards,
I have a feeling that we would want more than an institutional re-
view because that is partly what happened here. In other words,
just trusting the university isn’t going to cut it in something this
controversial ethically. Is that——
Mr. WAXMAN. Well, I don’t think an institutional review board is
trusting the university, and maybe we can have the experts inform
us on the subject. But I think an institutional review board is to
oversee the work of the universities and their proposals when they
evaluate the ethics of any experiment.
Mr. SOUDER. This is important to clarify because we had it in the
testimony in response to several questions. My understanding is
that unless you feel there has been abuse, the research on whether
there has been fraud, and the guidelines are standard, they submit.
Then they do an internal review, and unless you feel something is
wrong, you don’t review it. Is that correct?
Mr. WAXMAN. I think they have to review it in advance to pre-
vent an abuse, not wait till——
Mr. SOUDER. They set the guidelines, but to make sure that the
guidelines are being followed, it is self-reported unless somebody
blows a whistle or you suspect something. Is that correct, Mr. Pas-
cal?
Mr. PASCAL. Is your question to me?
Mr. SOUDER. Yes.
Mr. PASCAL. I am sorry. Yes. We normally get complaints of alle-
gations from individual scientists. Also, the institution is required
to report to us when they get to the investigation stage.
Mr. SOUDER. Thank you. Is that clarified?
Mr. WAXMAN. Well, I think it is an answer, and I appreciate the
answer. Thank you.
Mr. SOUDER. OK. Ms. Schmidt.
Ms. SCHMIDT. Thank you. I have a question. But before I ask my
question, Ms. Foxx said that language is important. And Dr.
Battey, this goes to you as well as the question. Language is impor-
tant, and I don’t think we should discuss the term ‘‘religion’’ when
we are discussing when life begins because I have a very dear
friend that is an atheist, and he believes the same as I do as to
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when life begins. And he doesn’t believe in any God or in any reli-
gion.
But having said that, I have been concerned about the issue of
appropriate stem cell research for some time. In my days when I
was in the Ohio Legislature, I actually went to the University of
Cincinnati to find out exactly how they were handling this. And so
I know that extrapolating information is important. And when I got
here, I did some research, and I found out that this committee in
its past has had a difficult time getting information from you.
As you know, and as I found out, this subcommittee requested
information from you in October 2002 seeking a detailed report
providing comprehensive information on the medical applications of
adult and embryonic stem cells, as well as cells from cloned em-
bryos and aborted fetuses. The subcommittee received a response
from you in June 2004, 20 months after its initial request, during
which time the subcommittee staff continuously inquired about the
status of this report, and subsequent chairmen’s letters were sent
seeking this material. And I have copies of them.
Your reply to this oversight request, 20 months in the making,
was completely insufficient and unresponsive to the plain meaning
of the committee’s request. Ultimately, you acknowledged this and
apologized for the inadequacy of the response.
But throughout this entire period, when Congress was seeking
critical information about these very issues we are discussing today
in 2006, information that would have been useful for complex pol-
icy decisions being faced by the Congress and our President, mem-
bers and their staffs were unable to obtain the kind of accurate,
timely, and up-to-date information from NIH necessary to do, quite
frankly, the people’s work.
This happened on your watch. It seems only appropriate that
while we are examining the problems in this research area, that
you explain to this body why such critical information was with-
held from Congress for so long. And the second part of that is: Will
you be forthcoming when we ask for additional information in a
timely manner and a comprehensive format in the future? Because
I believe the public has a right to know.
Dr. BATTEY. It is a fair question. I am very sorry that response
was delayed the length of time that it was. But I must inform the
committee that the NIH had developed its response within a few
weeks of when the request was initially received. Once we develop
a response, it is then subject to a clearance process in the Depart-
ment of Health and Human Services over which I have no control.
So yes, it was done on my watch, and I take responsibility for
it. But aspects of that delay were beyond my control. And what I
will tell you is that I will do what I can to get information to this
subcommittee or any other subcommittee, factual scientific infor-
mation, in as timely and accurate a fashion as the resources I have
at my disposal allow me to do.
But again, I say I am sorry you were without that information
for a 2-year period.
Ms. SCHMIDT. Well, I have a followup, sir. And again, I am new
to this process. But information is key——
Mr. SOUDER. Mr. Schmidt, will the gentlelady yield a second?
Ms. SCHMIDT. I would be honored, yes.
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Mr. SOUDER. And I will put your time back on. And if Ms. Norton
and Ms. Watson will let me make a brief comment, that I appre-
ciate your apology. Ms. Schmidt will have a followup question.
But in the role of oversight in the U.S. Congress—and this is not
directed at you—I am getting increasingly frustrated with this ad-
ministration coming up with multiple excuses as to why they can’t
give us documents on this, on HHS, on the State Department, on
the Office of Faith-Based, and other departments. We constantly
hear, well, it has to be reviewed.
We represent the American people. Two-year review is not ac-
ceptable. And I am not sure who we have to call in, whether we
have to do this at the full committee level. But other subcommit-
tees are having the same problem, in that exactly what takes 2
years of review to figure out, when we ask data and the data is
coming over to us, what kind of review has to happen for elected
officials to see the fundamental data.
Then second, then we are told that the process of why it took 2
years is pre-decisional, as though there was some sort of a political
discussion over what they were going to get us. And quite frankly,
both at Department of HHS under this Secretary and at the State
Department under multiple Secretaries, if it wasn’t for individuals
leaking us documents, we wouldn’t know that when we get the doc-
uments, often, what has been taken out.
And different agencies are saying—because we will make a docu-
ment request. Then we will be told that this is all the documents.
Then we will show the department—this happened three times in
one State Department request. This, I think, dealt with Afghani-
stan. And it is getting increasingly exasperating. Then you are sent
up here having to defend that.
But the bottom line is: We need timely responses. The type of re-
quests we made were basically factual requests. They shouldn’t
have had such a political screen. Even though we know this is a
difficult subject, we are the same party. We know how difficult the
subject is, but elected officials have a right to know what this data
is.
And the extra-exasperating part of this is that by the time we
get the data, then we don’t have the trust in the data. And then
we—in the example of the State Department—had to request
10,000 documents. And then they came back and said the great
cost.
Well, we lost confidence in the trust of the Department. And
HHS is headed this direction, too. If you can take this back. We
will try to target our document requests if we get them in a timely
fashion and get the documents that we requested. But if we don’t
get the documents requested in a timely fashion, we have to keep
broadening the search because we are an oversight committee.
And quite frankly, this happened under the last administration
until the last stretch, and then they started sending over like
truckloads of documents and taking forever to go through. But at
least they were more forthcoming. And I appreciate your willing-
ness to cooperate, and that this administration, hopefully at higher
levels than yourself, will start to respond. But the frustration is
building, and it is going to boil over if we can’t figure out how to
do it.
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So thank you for having the other data earlier. I yield to Ms.
Schmidt. But sorry, I wanted to go on the record that this is far
greater, even, than just his Department. We are having a tremen-
dous problem in doing oversight right now for this very reason, get-
ting 2 years and then not getting the—getting an incomplete
amount, and not knowing what we are missing. That is because we
don’t know what has been taken out.
Do you have any insight as to what took 2 years to review?
Dr. BATTEY. No.
Ms. SCHMIDT. Thank you, Mr. Chairman. As a followup, since
you had to put this through a review process, who are the people
we have to call to stop the delay in the review? Who—give me the
name, please, of the person that is accountable for the holdup in
this document request because as the chairman said, it is not just
Congress that has the right to know. It is the people that have the
right to know.
We represent the people of the United States. And we have the
right to know information in a timely fashion, sensitive information
on this issue, and this is a very controversial issue. If we don’t
have that information, we can’t make the appropriate policy deci-
sions that the people expect us to make.
So who at your Department held this up for 2 years, so we can
bring him in and ask why?
Dr. BATTEY. I don’t know.
Ms. SCHMIDT. Can you find that out for us?
Dr. BATTEY. I can try to find it out for you.
Ms. SCHMIDT. Thank you, Mr. Chairman.
Mr. SOUDER. Thank you. Ms. Norton.
Ms. NORTON. Mr. Chairman, I have a couple of questions, but I
want to just say a word because both gentleladies have mentioned
the word—the care we must take in language. And I want to sec-
ond what they said.
I want to say I appreciate that the gentlelady from North Caro-
lina said she wanted to be careful about her language when she
made analogies to the Tuskegee experiments involving living,
Black men who were treated in a way that was emblematic of the
way Black people were treated in the Southern States.
And I just want to say for the record, for those of you who want
to use those analogies into the African American experience, you
are right. You had best be careful. Because I believe I speak for Af-
rican Americans when I say we do not want anybody comparing
Black people to human embryos.
Mr. Chairman, I just want to say, because you have always been
very remedy-oriented and I was a little surprised at what you said
to the ranking member about BS’ing about analogies, we just heard
some analogies that, frankly, I resented.
But I really don’t think you meant that we are only interested
in the past. I have never seen you approach an issue that way. And
I know you don’t—you are not holding the hearing for political rea-
sons or to keep any information we get from these witnesses to our-
selves.
And Mr. Chairman, if I can remind you, our own Chair, Mr.
Davis, has said repeatedly that the Government Reform Commit-
tee, by the way, has the largest staff in the Congress of the United
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States because its writ is to investigate anything involving the
Government.
And I suppose the best indication of that, Mr. Chairman, for
something that some would argue is totally outside our jurisdiction,
is not only the hearings, not only the investigation, but the bill we
passed on baseball. I mean, there is another committee that has
primary jurisdiction over that matter, but the chairman brought
forward his own bill on it.
And I think when we are talking about this matter, we would
want to be remedy-oriented. And in light of my work with you on
this committee and my respect for your work on this committee, I
know that you would want us, if we could uncover some remedies
for adult stem abuses or embryonic stem abuses, to let everybody
know about it.
Let me have—let me ask a question to Mr.—Dr.—I think it is
Battey. Am I pronouncing that Right?
Dr. BATTEY. Yes, ma’am.
Ms. NORTON. And your role is the chair, of course, of this impor-
tant task force on stem cell research. And Mr. Pascal, who is a law-
yer, who speaks from another angle.
First of all, I was relieved that both of you appear to have testi-
fied that we don’t yet have this problem in this country, Dr. Battey,
that the vast majority are honest, do not reflect on even the poten-
tial on the human embryonic cell research one way or another.
You refuse to draw conclusions in advance. By the way, every-
body, that is how the scientific—how the scientific method works.
You come in with a hypothesis and you say, prove it one way or
the other. Prevent it if you can. Mr. Pascal says virtually the same
thing. Serious consequences if you had any particular case of—
great majority of scientists here are dedicated.
My question, and as far as you know have not been involved in
anything like this kind of fraud and human rights violation. Let me
ask you this. We talked about how fraud gets uncovered. Again,
going back to scientists, who first uncovered this fraud?
Dr. BATTEY. The initial——
Ms. NORTON. In Korea?
Dr. BATTEY. The initial allegations of fraud involved members of
the research team in Korea.
Ms. NORTON. Very important point to put on the record, that it
is a primary obligation of scientists themselves, as any ethical sci-
entist moves forward, to replicate, to investigate, and moves for-
ward in the spirit of great skepticism and that. But very important,
as we seek guidance—at least people like me seek guidance—from
the Federal Government, I don’t know what form it should take to
indicate how most fraud is uncovered, how most matters of this
kind are uncovered.
Are most of them brought forward by scientists, or was that un-
usual?
Dr. BATTEY. I will yield to my colleague, Mr. Pascal, who prob-
ably knows better than I do, but would comment that in my experi-
ence generally, they are brought forward by individuals familiar
with the research in question.
Mr. PASCAL. I would agree with that, that it is usually somebody
who is in the laboratory or the department and is familiar with the
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research being done so they have enough knowledge to know that
something is wrong.
Ms. NORTON. Whereas whistleblowers are uncommon in the Fed-
eral Government, that is the job of a scientist. And I am just
pleased to hear that for the most part, it seems to be working in
this country.
I have a question that bothers me very much, though, and this
involves the testimony of Mr. Schwetz—yes, of Mr. Schwetz, who
said that—in page 4 of your testimony that the guidance, the stem
cell guidance, does not generally meet the—your definition, HHS
definition, of human subjects research, and that is where you have
offered guidance. Is that correct?
Mr. SCHWETZ. Let me clarify because there are circumstances
where research involving stem cells would be human research that
would have to be reviewed and approved by an institutional review
board, and you would have to have——
Ms. NORTON. No. I am trying to establish—I am not trying to un-
derstand that. What I am trying to establish is that you have no
guidance involving stem cell research.
Mr. SCHWETZ. Yes. We do have guidance to the IRB and inves-
tigator community on their responsibilities if they are doing re-
search involving stem cells. We do have guidance on that.
Ms. NORTON. So the guidance you have—the guidance you have
offered would keep—in your judgment, would alert the scientific
community that the kind of abuses we find in South Korea are
not—or violate, I guess, your regulations and U.S. law?
Mr. SCHWETZ. I am not sure I really understand your question.
But there are some circumstances where fraud would represent
risk to subjects. But there are other—to research subjects. There
are other cases where fraud would not necessarily represent risk
to subjects of research, but would have other implications for the
quality of the data that are coming out of a laboratory.
Guidance that we have put out regarding research involving
human subjects and stem cell research is meant to be taken in the
context of our broader regulations that tell investigators and the
IRB community how to ethically review the research.
Ms. NORTON. Dr. Battey, one last question. Are you aware of the
research—they have been very careful in how they have described
it. I have read it. I have seen some of it on television involving
rats, where rats have been injected with human embryonic cells.
These rats were totally paralyzed before, and you see that the rats
now move, awkwardly but amazingly and astoundingly.
Without commenting on where this would lead because I don’t
think anybody knows where it would lead, and those who have
been involved in this astounding, this startling, this amazing re-
search are careful to say that these are rats only, but they were
injected, were they not, with embryonic human stem cells?
Dr. BATTEY. I believe that is correct.
Ms. NORTON. Very important to note since we had all kinds of
opinion from non-scientists on the other side that there is no
progress whatsoever. And Congress, however, knows best.
Thank you very much, Mr. Chairman.
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Dr. BATTEY. I am. Could I add just one comment, though? It is
not clear in what way the embryonic stem cells are enabling the
rats to move their hind legs again.
Ms. NORTON. That is precisely why this work is going on, Dr.
Battey. And in fact, you know, I mention it only because of the im-
plication on the other side that there is no evidence of any results
from embryonic—not because——
Mr. SOUDER. He just said there was no evidence.
Ms. NORTON [continuing]. And to their credit—to their credit, I
have to say not because even those who are responsible for this——
Mr. SOUDER. Ms. Norton.
Ms. NORTON [continuing]. Scientific feat have said, hey, right
around the corner, guess what? Everybody who is paralyzed is
going to walk. All they have said is, we have a moral obligation——
Mr. SOUDER. He said——
Ms. NORTON [continuing]. To proceed with this——
Mr. SOUDER. Ms. Norton, your time is well past.
Ms. NORTON [continuing]. With this kind of scientific research.
And I agree they do.
Mr. SOUDER. There is no evidence. What he said is there is hope
in that research. His opinion gives hope, among other potential re-
search. But there is no evidence.
Ms. Watson.
Ms. WATSON. Thank you, Mr. Chairman. And thank you for this
oversight hearing on the issue.
In listening to the questions my colleagues have asked, there was
a mention of the challenges of when life begins and so on. And in
reading through the materials that were prepared for this hearing,
it comes to light that the Korean government had approved of Dr.
Hwang’s research.
Now, my question is: Do we have a bioethic commission similar
within your Department, NIH or HHS? And do we run papers
through it? When they have come up with a new piece of research,
what do we do in response? Because in other countries, the ethics
and morals and principles upon which they might do research can
differ with the country, the culture, and tradition.
And what do we do when we receive something called research
and, you know, the controversy is over the fact that he misrepre-
sented how he got the ova. So our concern should be: How do we
protect our research and not allow this to happen? So can you re-
spond?
Dr. BATTEY. I will respond to the best of my ability. You are cor-
rect in pointing out that there are different national standards for
providing Government funding or private funding for research in
the area of human embryonic stem cells and human somatic cell
nuclear transfer.
Right now, the Department of Health and Human Services is op-
erating under the President’s policy as well as legislative language
that is on the DHHS appropriation. The legislative language pro-
hibits the use of DHHS funds for human embryo research. This is
often called the Dickey language.
The President’s policy allows Federal funds to be used for human
embryonic stem cell research so long as the embryo was created for
reproductive purposes; was no longer needed for those purposes; in-
VerDate 11-MAY-2000 11:15 Dec 14, 2006 Jkt 000000 PO 00000 Frm 00067 Fmt 6633 Sfmt 6633 D:\DOCS\29580.TXT HGOVREF1 PsN: HGOVREF1
64
formed consent was obtained from the donors; and no fiduciary in-
centive was provided for the donation of the embryo, with the con-
dition that the inner cell mass be removed from the 5-day-old blas-
tocyst on or before 9 p.m. Eastern Daylight time, August 9, 2001.
So the policy under which DHHS currently operates is a policy
that oversees the use of Federal funds for research. There is no na-
tional policy governing this research when the funds being used
come from sources other than the Federal Government. And there
is a patchwork of regulations in various States that provide dif-
ferent sets of guidelines for the legality or the provision of funds
for this area of research.
Ms. WATSON. I think you make my point. And if we are results-
oriented and remedy-oriented, and I too must agree with my col-
league that our Chair seems to try to get to that point, and I appre-
ciate that because that is the function of our committee, to have
that kind of oversight.
I would hope that you and maybe HHS could come together and
talk about what the standard would be for Federal funding. We
cannot control what other countries do. We look at their results
and we look at the 50 States, and I know I chaired a committee
where we dealt with this issue.
We look at—as you say, they are a patchwork. But maybe we
could develop some standards that would be guidelines. And when
we read a piece of research that comes from another country, it has
to go through a screening process before we make a big deal over
it. You know, that is the way the Koreans dealt with this. The pro-
fessor resigned. The doctor resigned, but he is going to go on with
his research. So there is a cloud over whatever he produces.
But I think we ought to set some standards where anything that
comes from abroad flows through. And we ought to have a bioethics
unit through which they go so we can discuss, you know, all these
different theories and all these different ethics, and separating
church from State, and, you know, what I believe in my religion
versus what you believe. You are the scientist, and all.
So I would like you to respond to that. I think I heard you men-
tion that we needed something like that. Can you respond, please?
Dr. BATTEY. You raise a very interesting issue. My response is
that the fraud that was perpetrated in South Korea is reprehen-
sible to everybody in the scientific community, every physician that
I know in this country, and in fact, every responsible citizen that
I know.
It was wrong. It should never have happened. It was revealed be-
cause responsible individuals, subordinates within the laboratory,
brought forward allegations. And in a very short amount of time,
the problem was explored and revealed, and the fraud revealed to
the entire world, and Dr. Hwang discredited.
Had this individual not come forward, when it became apparent
that no one else could reproduce his results, his results would have
fallen into discredit. So we have a process that sorts out the truth
from fabrication. And the linchpin of that process is reproducibility
in another laboratory. And it isn’t science if it can’t be reproduced
in another laboratory.
Ms. WATSON. Did you want to mention my suggestion that we
look at the bioethics and try to work that piece out so that when
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you come forth with your empirical evidence that this can be dupli-
cated, we have run it through these tests, including our discussion?
Because I think there is a future for this research, and particularly
here in this country. But we want to be sure that we can avoid the
fraudulent practices up front.
Dr. BATTEY. I think that is an interesting suggestion that should
be considered by those who are higher ranking than I am in the
administration.
Ms. WATSON. Well, I throw that out for whoever is listening.
Maybe it will get into the press and somebody will start consider-
ing it.
Thank you so very much, panel.
Mr. SOUDER. I want to also thank this panel. We will most likely
have some written questions. Hopefully we can get a timely re-
sponse. We will leave the record open longer than 3 days. But if
we can’t, my inclination will be to write that we could not get clear-
ance of the Secretary of HHS, OMB, and the White House for the
answers because we will try to keep the questions narrow enough.
When this hearing book comes out, it should include a fair amount
of data with that.
I also want to clarify two things that Ms. Norton said. She is cor-
rect that we do—in this committee, what I said is we look back on
the past. We look in the past, at Katrina, at steroids, at whatever
the issue is, to try to then develop and highlight what can be solu-
tions that would then move to legislative committees. And so we
have a future orientation by looking back on the past, and I didn’t
mean to imply we didn’t have a future orientation.
The second thing, but I do think the record needs to reflect this:
This committee does have jurisdiction over both the oversight on
baseball, but also the legislation. There was a difference of opinion,
which we have worked out, that if the steroid was overseen by the
Office of National Drug Control Policy, it would be our legislative
as well as oversight. If it is DEA, it is Judiciary. If it is FDA, it
is Energy and Commerce.
The only question of where jurisdiction fell was on oversight, and
that is really what we are battling over because we did have—in
narcotics, we do have legislative as well as oversight. So I wanted
the record to show that.
I once again thank this panel. Thank you for your time, and I
look forward to continuing to work with you.
If the second panel could come forward.
Dr. BATTEY. Thank you, Mr. Chairman.
Mr. SOUDER. Thank you.
Our second panel is Dr. Richard Chole, Lindberg professor and
chairman of the Department of Otolaryngology—the subcommittee
stands in brief recess.
[Recess.]
Mr. SOUDER. The subcommittee will come to order.
Our second panel is Dr. Richard Chole, Lindberg professor and
chairman, Department of Otolaryngology, Washington University
School of Medicine, St. Louis; Judy Norsigian, executive director,
Our Bodies Ourselves, co-author of ‘‘Our Bodies, Ourselves’’; Dr.
Diane Beeson, professor emerita, Department of Sociology and So-
cial Services, California State University, East Bay; Mr. Richard
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Doerflinger, deputy director of secretariat for pro-life activities, the
U.S. Conference of Catholic Bishops; Dr. Debra J.H. Mathews, as-
sistant director for science programs, the Phoebe R. Berman Bio-
ethics Institute; and Joe Barden—Brown, excuse me, Parkinson’s
Action Network State coordinator of Texas.
If you will each stand—well, why don’t I swear the four of you
in, and then I will catch the other two, maybe, by the time we do
the third one.
[Witnesses sworn.]
Mr. SOUDER. Let the record show that Dr. Chole, Judy Norsigian,
Richard Doerflinger, and Joe Brown all responded in the affirma-
tive. We will swear in the other two witnesses before their testi-
mony.
We will start Dr. Chole. Thank you for coming.
STATEMENTS OF RICHARD A. CHOLE, M.D., Ph.D., LINDBERG
PROFESSOR AND CHAIRMAN, DEPARTMENT OF OTOLARYN-
GOLOGY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE,
ST. LOUIS; JUDY NORSIGIAN, EXECUTIVE DIRECTOR, OUR
BODIES OURSELVES, CO-AUTHOR OF ‘‘OUR BODIES, OUR-
SELVES’’; JOE BROWN, PARKINSON’S ACTION NETWORK
STATE COORDINATOR, TEXAS; DIANE BEESON, M.A., Ph.D.,
PROFESSOR EMERITA, DEPARTMENT OF SOCIOLOGY AND
SOCIAL SERVICES, CALIFORNIA STATE UNIVERSITY, EAST
BAY; RICHARD DOERFLINGER, DEPUTY DIRECTOR, SEC-
RETARIAT FOR PRO-LIFE ACTIVITIES, U.S. CONFERENCE OF
CATHOLIC BISHOPS; AND DEBRA J.H. MATHEWS, M.A., Ph.D.,
ASSISTANT DIRECTOR FOR SCIENCE PROGRAMS, THE PHOE-
BE R. BERMAN BIOETHICS INSTITUTE, JOHNS HOPKINS UNI-
VERSITY
STATEMENT OF RICHARD A. CHOLE
Dr. CHOLE. Thank you, Mr. Chairman. I am Richard Chole. I am
a professor at Washington University, but I am not representing
Washington University but rather myself as a private citizen.
I am a physician and a scientist. I have been funded for about
25 years by the institute, actually, that Dr. Battey directs. I am
going to restrict my comments because of a lot of territory that has
been covered already.
Biomedical sciences are on a brink of a real revolution in the de-
velopment of our science. This is the era of regenerative medicine.
This is an exciting area. It is not necessarily a new area, but it is
the result of incremental change over several decades. These incre-
mental changes continue to occur. This might in the future allow
us to not only ameliorate and manage disease, but actually cure
some diseases. Organ transplants are an example of the beginning
part of that.
While the potential to help mankind is great, this new era poses
some ethical and moral issues that we have never really encoun-
tered before that must be addressed not only by the scientists and
physicians doing the research, but the public, probably more impor-
tantly by the public.
The source of these regenerative cells for regenerative medicine
will come from a variety of sources, and I would like to briefly dis-
cuss a couple—make a couple of comments about these sources.
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They might be embryonic, at the very earliest part of develop-
ment. They might be fetal, at later parts of development. Or they
may be adult, so-called adult, from the time of birth on. All of these
sources of regenerative cells are called stem cells in that they can
differentiate into any particular type of tissue. Some are more re-
stricted than others.
Embryonic stem cells, as we have been referring to them, come
from the very earliest human embryos, those from the stage of fer-
tilization, the zygote, through the blastocyst, about 5 to 9 days. In
order to get the embryonic stem cells from these early embryos, the
early human embryo must be destroyed. And this is a human being
at the earliest stage of developmental life.
Those inner cells, that inner cell mass, are the stem cells. They
then are the ones that have been studied to lead to differentiation
into different types of tissues. And indeed, scientists have been able
to coax these cells to develop into a variety of types of tissues with
potential uses for medical therapeutics.
Research into these cells has been incremental, and unlike the
hype in the popular press, these have not been major break-
throughs but incremental, very small breakthroughs, showing some
difference between experimental and control animals. The pitfalls
of this type of research are that by definition, it requires the de-
struction of a living human being at the embryonic stage.
There are others as well. An embryonic stem cell is a different
person. If you take the cells from that person and then put them
into a different individual, there is a rejection process that goes on.
That rejection would lead to the destruction of those cells unless
the person was immunosuppressed by very powerful drugs.
These cells by nature are vigorous growers. They don’t know
when to stop growing in many cases, and most of this research has
resulted in implantation of these cells where they will grow rather
uncontrollably into tumors called teratomas. This particular ques-
tion has not been answered.
These cells, once transplanted into an individual, may not—al-
though they may function like a particular type of cell, may not be
controllable. And in that environment, they may make too much of
a hormone or not enough of the hormone. And there is no reason
to—no evidence that these can really be controlled.
So those are some potential problems with embryonic stem cells.
One of those problems, that they may be rejected, may be sur-
mounted, scientists say, by cloning them. Cloning, as we have
heard, is the placement of a nucleus from the body into an empty
egg from an egg donor. This develops into a zygote and then a blas-
tocyst.
If it were done in a human being, and it has never been done
in a human being, this would recreate a living human being at the
embryonic stage. The same ethical issues are faced by destroying
this human being, albeit a cloned human being, if that were indeed
possible. The advantage of this, theoretically, would be there would
be no problem with cell compatibility. And I think that is why the
excitement about this.
The difficulties are many. These cloned embryos are not normal
embryos. Dolly was not a normal sheep. It took 250-plus times to
get a cloned embryo from a sheep to become Dolly the lamb. These
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cells have many, many different problems. They are defective em-
bryos, and they are defective cells.
These stem cells in cloned embryos are defective stem cells. So
they are not normal at all. They are defective. And the idea of
using a defective embryonic stem cell that really can’t be controlled
for medical therapeutics is pretty conjectural thinking and far, far
off from current scientific knowledge.
On the other hand, adult stem cells have their advantages and
disadvantages as well. Adult stem cells, which are cells in our
body—the most notable ones are in bone marrow, bone generation
cells—have been shown to have more and more potential in devel-
opment into specific tissue types. We have found recently that
these cells can be caused to de-differentiate and become more like
elementary stem cells, and can then be guided to develop into other
types of tissue.
This line of research has great promise because it is taken
from—the cells are taken from the individual, and there are no
compatibility or rejection problems when the cells are given back.
It also has great potential because of the variety of diseases that
can be treated with it, and in fact, we treat many diseases with it
in common clinical practice, and clinical trials in humans for lupus
and heart problems and other problems have showed very promis-
ing results.
So the opportunities for adult stem cells are tremendous. There
are disadvantages of adult stem cells, of course, in that they don’t
have all of the potential of an embryonic cell. But the problems can
be overcome by further research into how these are developed.
I would like to just make a comment about this question of when
life begins. It is my contention that life begins at the fertilization
of the egg and the development of the zygote. Every, single person
in this room was once a zygote, a unique zygote. From the time of
the fertilization of the egg until this moment, it has been a process
of your development. The genes were set. You are a human being
at that point.
Medical science really has had little question about that, and I
will read to you from a couple of textbooks that I took off the shelf
at Washington University.
The first one: ‘‘The development of a human being begins with
fertilization, a process by which the spermatozoon from the male
and the oocyte from the female unite.’’
Another textbook: ‘‘Union of these gametes’’—that is, the sperm
and the egg—‘‘during fertilization produce the zygote or fertilized
ovum, which is the beginning of a new human being.’’
Another one: ‘‘Although life is a continuous process, fertilization
is the critical landmark because under ordinary circumstances, a
new, genetically distinct human organism is formed.’’
So, really, there has never been any question in the teaching in
embryology and the textbooks, maybe until the current era—these
may be changed—that life begins at that point.
Finally, I would like to make a comment about scientific hype
and hype in the press about this.
Mr. SOUDER. You need to summarize. We let you go over 2 min-
utes.
VerDate 11-MAY-2000 11:15 Dec 14, 2006 Jkt 000000 PO 00000 Frm 00072 Fmt 6633 Sfmt 6633 D:\DOCS\29580.TXT HGOVREF1 PsN: HGOVREF1
69
Dr. CHOLE. OK. In the popular press, one might get the impres-
sion that paralyzed rats can walk again. This is incorrect. The
studies have shown that when the experimental animals are com-
pared to the control animals, both recover quite well in the experi-
ments that she was citing, but the embryonic stem cell animals re-
cover a little bit better. It is not the contrast that has been depicted
in the popular press.
This drama to this field has led some scientists to assume the
position of celebrity. Scientists are not prepared to be celebrities.
The scientist’s role is to use cold, dispassionate analysis for his or
her data, and then present it in an honest way. This element of ce-
lebrity has led to some distortion, maybe the distortion that led to
the big scandal in Seoul.
Thank you very much.
[The prepared statement of Dr. Chole follows:]
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Mr. SOUDER. Thank you very much.
Our next witness is Judy Norsigian.
STATEMENT OF JUDY NORSIGIAN
Ms. NORSIGIAN. Thank you, Chairman Souder, Mr. Cummings,
and members of the committee for the opportunity to speak. Judy
Norsigian, executive director of Our Bodies Ourselves, a women’s
health education and advocacy organization, best known for our
landmark book about women’s health and sexuality, ‘‘Our Bodies,
Ourselves.’’
At the outset, let me make clear, as I did at similar hearings 4
and 5 years ago, that my organization supports most embryonic
stem cell research. We fully support ESC research that utilizes oth-
erwise discarded embryos from IVF clinics. Thus, we do not agree
with President Bush, for example.
At the same time, we have serious concerns about a small subset
of ESC research known as somatic cell nuclear transfer, more com-
monly referred to as research cloning, therapeutic cloning, or em-
bryo cloning, as we have discussed today. My organization believes
that our country should follow the prudent example already adopt-
ed by Canada and place a moratorium on all SCNT research until
better safety data are available for some of the drugs used during
multiple egg extraction procedures.
There are several reasons for this position, but I will focus my
remarks primarily upon our concerns regarding the risks of mul-
tiple egg extraction. And although women who undergo these pro-
cedures experience similar risks whether doing this for reproduc-
tive purposes, as is the case in an IVF clinic, or for research pur-
poses, there is a critical difference.
In the former instance, there is a 10 to 40 percent chance that
someone, either the woman herself or another woman who is seek-
ing to become pregnant at an IVF clinic, will be able to have a
baby. That is a clear benefit. In the latter instance, when a woman
undergoes these procedures solely for research purposes, the bene-
fits to her or someone else are far more dubious at this time.
Although some stem cell researchers have discussed this matter
and even share our concerns, few have been willing to write about
these issues. It may be that one positive outcome of the scandal in
South Korea will be greater recognition of just how risky multiple
egg extraction can be, as well as how easily frenetic competition
and unjustified hype can lead to a more ready dismissal of these
risks.
In a recent issue of the American Journal of Bioethics, Stanford
faculty David Magnus and Mildred Cho write the following: ‘‘In a
previous paper, we argued that there were risks associated with
being an oocyte donor that were not given adequate attention in
the informed consent process. This claim was based upon the in-
formed consent documents by the South Korean researchers, an ac-
companying written description of the consent process, and their
responses to questions posed.’’
‘‘We argued that it would be easy to give short shrift to the small
but serious risks that typically arise in a clinical setting precisely
because these risks are not associated with the research aspects of
oocyte donation.’’
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They go on to say that: ‘‘The language used to describe scientific
experiments also makes a great deal of difference in how accurately
we convey the nature of stem cell research.’’
Finally, they say, ‘‘There is an important distinction between oo-
cyte donation for research and live organ donation for transplan-
tation. Live organ donation has a clearly established clinical value.
Stem cell research does not. If that should change, we would agree
that allowing women to donate oocytes for stem cell-based treat-
ments would be permissible, if conducted properly. But allowing re-
search donation to take place under these circumstances is an invi-
tation for a new kind of therapeutic misconception, and should be
avoided at this early stage of scientific development.’’
The risks of multiple egg extraction are not well-enough studied,
especially the risks associated with the drugs most often used to
suppress a woman’s ovaries. Lupron, generally referred to as
leuprolide acetate, the generic term, is the drug I would like to
focus on now.
I have listed many of the adverse reactions in my testimony.
These include: pituitary and liver function abnormalities; chronic
joint, muscle, and bone pain; headaches and migraines; dizziness
and blackouts; and serious memory disturbances and brain fog that
persist well after the drug is discontinued.
And we have had this from numerous reports. The FDA has re-
ceived numerous adverse drug reports, and one of the things we
are hoping we will see in the near future is a data mining analysis
by scientists at the FDA to give us better direction on what kind
of research we need to conduct.
Lupron’s use in the IVF setting is off-label use, and as former
Chief Medical Officer Suzanne Parisian pointed out in her memo-
randum of February 2005, there are serious safety concerns yet to
be resolved. Only well-designed research will answer critical ques-
tions that would then allow true informed consent for women un-
dergoing multiple egg extraction procedures for any purpose.
The drugs used to hyperstimulate the ovaries after ovarian sup-
pression also have negative effects, most notably Ovarian
Hyperstimulation Syndrome, a condition in which the ovaries con-
tinue to enlarge even after the eggs have been collected. Serious
cases of this syndrome involve the development of many cysts and
massive fluid buildup in the body. Rarely, death has resulted. The
most recent one documented was in England in December.
And it is not only the women undergoing the procedures who
may be at risk from ovarian hyperstimulation. A very important
article published in the past month by a Dutch team including
medical and basic scientists suggests that infants may also suffer
adverse consequences.
This group has shown that female mice subjected to ovarian
hyperstimulation had offspring with reduced birth weight as well
as a high incident of congenital anomalies, including delayed for-
mation of bones and an eightfold increase over background levels
of cervical ribs, a condition which, when present in human infants,
is associated with stillbirth and cancer.
Should SCNT research go forward despite the concerns men-
tioned here, it will be left to women’s health advocated to empha-
size the inadvisability of women undergoing these procedures, espe-
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cially younger women, whose risk of Ovarian Hyperstimulation
Syndrome is actually greater than that for older women.
Also, if such research does go forward, certain regulations and
oversight of the research with respect to egg procurement are es-
sential. I have listed seven here: that eggs should be obtained with-
out any hormonal stimulation, since there is still insufficient infor-
mation to get true informed consent. No relatives or coworkers of
those doing research on eggs should be allowed to provide eggs for
research.
All medical expenses resulting from egg extraction for research
should be covered; in cases where would be hormonally manipu-
lated, longer-term healthcare coverage may be necessary to provide
medical care for certain delayed health problems.
Those performing egg extraction for research purposes should
function totally separate from IVF services. And no research should
be allowed on eggs or stem cell lines developed from eggs procured
by means other than those just mentioned. This would avoid use
of stem cell lines created in other countries or regions where safe-
guards to women’s health might not be in place.
We also believe that no patents should be allowed for products
that might result from research on these eggs. Without such a pol-
icy, many therapies will likely never be accessible to the wider pub-
lic. I can give you other such examples already. In addition, it
would be extraordinarily difficult to avoid a problematic commer-
cial market in women’s eggs.
And, of course, no payment to egg providers beyond direct ex-
penses. We think both the researchers and the women who provide
eggs in this case may be going to be making a sacrifice.
So in conclusion, many scientists now acknowledge that individ-
ualized disease third parties will not research from embryo cloning
research anyway, in part because of the need for massive numbers
of eggs. The main benefit of embryo cloning would be the ab light
to develop research models for studying particular diseases and
conditions, but some of this type of work can be done already with
otherwise discarded embryos that result from PGD, pre-implanta-
tion genetic diagnosis, testing.
At this point in time, given both the known and unknown risks
involved in multiple egg extraction procedures, these procedures
should not be done solely for SCNT research. At the same time, we
do support most embryo stem cell research.
Thank you.
[The prepared statement of Ms. Norsigian follows:]
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Mr. SOUDER. Thank you.
I am going to move to Mr. Brown next because he has an air-
plane to catch.
STATEMENT OF JOE BROWN
Mr. BROWN. Thank you, sir. Thank you, Mr. Chairman and mem-
bers of the subcommittee, for inviting me today. My name is Joe
Brown. I am a State coordinator for the Parkinson’s Action Net-
work, a founding member and vice president of Texans for Ad-
vancement of Medical Research, and a founding member of the Al-
liance for Medical Research. I have been an advocate for 20 years.
As someone living with chronic disease, as a patient and an ac-
tive caregiver, I was dismayed when I read the memorandum pub-
lished by the committee that appeared to reach pertinent conclu-
sions before this hearing was convened. It mistakenly concluded
that somatic cell nuclear transfer [SCNT], is not supported by cur-
rent science, and those who support this research have created an
unjustified hype that plays on the hopes of suffering patients.
I am not going to talk about theory and intellectual concepts. I
am going to talk about life—my life, my wife’s life, and the lives
of you and your families.
Having watched a genetic form of Parkinson’s slowly steal the
quality of life from my beautiful wife, I am concerned for my chil-
dren and grandchildren. I have lived 70 years with a genetic heart
condition that has sudden death as its most significant side effect.
I have been fortunate enough to survive three heart attacks, by-
pass surgery, cardiac arrest, and cancer.
I have reason to hope, especially since I have benefited from re-
search that was thought to be wrong and unethical. I was the ninth
person in the United States to receive a procedure that took me
from being unable to walk from one room to another and days filled
with countless hours of angina, to being able to carry my grand-
child up a flight of stairs.
This procedure, which actually gives the patient a heart attack
to reduce obstructive heart muscle, was originated by a Swiss car-
diologist. Switzerland didn’t believe that giving heart attacks was
ethical and wouldn’t allow the procedure. The quality of my life
was improved because Dr. Sigwart was forced to leave his country,
just as American scientists are doing today in order to pursue stem
cell research.
So yes, as a patient, I do have hope that SCNT will succeed. But
it is not unjustified hope. The breakthroughs have been exciting
and amazing, but I recognize that sound research takes time. It
took 52 years for the polio vaccine to get to market. I don’t expect
the scientific community to have these treatments or cures avail-
able in my lifetime, but if we don’t start now and start solving the
problems that we have with communication with each other, the
cures won’t be there for our children and grandchildren.
When I visited the University of Texas Medical Branch in Gal-
veston, scientists working with adult stem cells told me the most
significant advances in adult stem cell research have occurred since
embryonic stem cells were first isolated in 1998. The reason these
scientists gave me is the embryonic stem cells are teaching them
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how to work with adult stem cells. To promote one form of stem
cell research to the exclusion of another is counterproductive.
I am astounded that there are those who don’t recognize, while
there may be fraudulent researchers, by definition, it is impossible
for research in and of itself to be fraudulent. We don’t stop basket-
ball games when a player is called on a foul, nor do we stop having
congressional sessions due to a Representative’s misconduct.
In the future, as the past, scientific fraud will be detected when
peers are unable to replicate the results. And unfortunately, this
self-policing mechanism has been disengaged in our country be-
cause the Federal Government isn’t supporting the research.
The fact that one scientist apparently procured egg donations
without appropriate attention to the welfare of the patients doesn’t
mean that everyone else will do the same. Women have a right to
donate eggs for the benefit of others when properly informed and
with informed consent.
It is incumbent on the United States, where both the quality of
science and dignity of life are of uppermost concern in all of our
minds, to take the lead in creating an appropriate framework for
stem cell research while promoting and protecting its progress.
On behalf of my family and the more than 1 million Americans
with Parkinson’s disease who would benefit from this research
moving forward, I appreciate the opportunity to provide testimony
to the subcommittee today.
[The prepared statement of Mr. Brown follows:]
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Mr. SOUDER. Thank you, and whenever you feel you need to head
to the airport——
Mr. BROWN. It is going to be a little while.
Mr. SOUDER. Now, I did the full introductions. But Dr. Beeson
and Dr. Mathews, I need to swear you in yet. So if you will both
stand and raise your right hands.
[Witnesses sworn.]
Mr. SOUDER. Let the record show that both Dr. Beeson and Dr.
Mathews responded in the affirmative. And I will go to Dr. Beeson.
STATEMENT OF DIANE BEESON
Ms. BEESON. Thank you, Chairman Souder, Representative
Cummings, and committee members. I appreciate being invited to
testify today.
My name is Diane Beeson. I am medical sociologist and professor
at California State University, East Bay. For over 30 years, I have
conducted research on social issues related to genetics and new re-
productive technologies. I am a lifelong supporter of women’s abor-
tion rights, and I support embryonic stem cell research using em-
bryos left over from IVR treatments.
Like many social scientists, I have broad concerns related to the
wisdom of developing cloning technologies. However, today I will
focus on the most immediate social and ethical problems created by
the demand for human eggs needed in experimental cloning, or
SCNT, and that is the threat to women’s health.
Dr. Hwang and his colleagues used over 2,000 eggs without pro-
ducing even one clonal embryo. This means we still do not know
how many thousands or tens of thousands of eggs this research
may require before achieving even preliminary success. Further-
more, it has become clear that payment, coercion, and lying were
used to acquire the eggs that the media reported many women
were eager to donate.
Because egg extraction has come into expanded use since the
birth of the Nation’s first test tube baby in 1981, it is often as-
sumed to be safe. Unfortunately, this is not the case. The fact is
that egg extraction as currently practiced poses inadequately un-
derstood but clearly significant risks to the health of women.
As you have heard from Ms. Norsigian, extraction of eggs in-
volves introducing powerful hormones into a woman’s body to ma-
nipulate it into producing many eggs at a time rather than the nor-
mal one or two. It often uses drugs not approved for this process,
off-label, or drugs for which no long-term safety data are available.
The FDA currently has on file over 6,000 complaints regarding
Lupron alone, including 25 reported deaths. These complaints must
be investigated and analyzed before more women are exposed to
such potential dangers.
We know that a coalition of Korean women’s organizations is
suing their Government for damage to the health of Korean egg
providers. Scientific replication will not help these women.
We should understand that the problems related to egg extrac-
tion are not unique to Korea. I have included with my testimony
a letter from the mother of a young woman who died an agonizing
death from Ovarian Hyperstimulation Syndrome in Dublin in 2003.
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Last April in London, another young woman dropped dead from a
massive heart attack at a bus stop, linked directly to OHSS.
While such events appear to be rare, it is possible that many
deaths and other longer-term side effects have simply not been
linked officially to the egg extraction procedures that preceded
them. And if we look at the history of the use of hormones in this
country, with DES particularly, we find that it often takes 30 years
and hundreds of thousands of women being hurt by these things
before they are taken off the market.
A former Chief Medical Officer of the FDA, in a letter I have at-
tached to my written testimony, reminds us that, ‘‘Studies to date
have not ruled out a possible link between stimulation drugs and
increased risk of ovarian cancer.’’
Another destructive consequence of ovarian hyperstimulation for
women may be serious abnormalities in their children. Just this
month, a new study reports that ovarian hyperstimulation treat-
ment in mice results in several significant abnormalities in their
later offspring. One in particular is associated, in humans, with an
increased incidence of deformities and cancer.
These concerns must be investigated before involving thousands
of women in egg extraction purely for research purposes. Informed
consent to participate in egg extraction is not possible without first
following up on these serious warnings, particularly in the context
of research.
Informed consent is also made difficult by the fact that scientists
and other proponents of SCNT have been reluctant to confront
forthrightly the dangers related to egg extraction. Certainly in
California this has been the case.
This reluctance is a function of conflicts of interest resulting from
recent legal changes affirming the right to patent genetically engi-
neered life forms, and also allowing universities and their research-
ers to patent even those research products funded by the Federal
Government. As a result, the field of embryonic stem cell research
has become a virtual biotech gold rush.
Under these conditions, it is highly unlikely that any regulation
can adequately manage the ethical quagmire created by moving
forward with SCNT. As a society, we are at a turning point in our
relationship to science. We are being asked to make women the
servants of biotechnology rather than insisting on a biotechnology
that promotes the well-being of all people.
For these reasons, until we understand more fully its human
costs, I strongly urge your support for a moratorium on somatic cell
nuclear transfer in both publicly and privately funded contexts.
Thank you.
[The prepared statement of Ms. Beeson follows:]
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Mr. SOUDER. Thank you very much for your testimony.
We will now go to Mr. Doerflinger. Thank you very much for join-
ing us.
STATEMENT OF RICHARD DOERFLINGER
Mr. DOERFLINGER. Thank you, Mr. Chairman.
As we know, Korean researchers led by Dr. Woo Suk Hwang are
now seen as having perpetrated a massive fraud, details of which
have been ably described here by others. I think there are sci-
entific, political, and moral lessons to be learned from this. Each
point here is documented in my longer written statement I have
submitted for the record.
First, the scientific lesson: Cloning researchers must go back to
the drawing board. After 8 years of effort to clone human embryos,
no one has achieved even the first step in using this procedure for
human treatment, so-called therapeutic cloning.
Usually, fraud by one researcher does not discredit an entire
field, but Dr. Hwang’s studies were the field of allegedly successful
human cloning for research purposes. If his research is a fraud,
there is at present nothing left of that field. As the New York
Times says, ‘‘Cloning researchers are back to square one.’’
This is, by the way, the third time in 8 years we have heard an-
nouncements of success in cloning human embryos for their stem
cells, only to find the claim had little basis in fact. The other false
starts, in 1999 and 2001, were by Americans. South Korea has no
monopoly on misleading hype in this field.
And let me just say, the word ‘‘fraud’’ is used, and it is perfectly
appropriate. But Dr. Hwang did not start as a fraud. He started
as someone trying to make this work. And after years of attempt,
endangering the health of 100 women, thousands of eggs, creating
hundreds of embryos in the lab, with those tens of millions of dol-
lars and the full Government support of South Korea, just like ev-
eryone else, he failed.
And that is why he was tempted, in his desperation, to commit
fraud. He is the biggest fraud in this field, but the key word that
is common to all the cloning researchers, is failure, failure, failure.
And I heard some subcommittee members say, therefore, this is the
very sort of thing the Federal Government has to get into funding.
Attempts at therapeutic cloning in animals have also been dis-
couraging. In several studies, researchers achieved any therapeutic
goal only by implanting the cloned embryos in an animal’s uterus
and growing it to the fetal stage, then killing it for more developed
fetal stem cells.
Such fetus farming is now seen by some researchers as what
they call the new paradigm for therapeutic cloning, and some State
laws on cloning have even been crafted to allow such grotesque
practices in humans. This would compound cloning’s exploitation of
women as egg factories by exploiting them as incubators for cloned
humans as well.
What are the implications of embryonic stem cell research in
general? There is a distinction. It depends on whether cloning is es-
sential for progress in embryonic stem cells. Cloning supporters
used to say it is essential. Now that judgment is being reversed.
VerDate 11-MAY-2000 11:15 Dec 14, 2006 Jkt 000000 PO 00000 Frm 00116 Fmt 6633 Sfmt 6633 D:\DOCS\29580.TXT HGOVREF1 PsN: HGOVREF1
113
Evan Snyder, in the New England Journal of Medicine, said
cloning plays only a minor role. One recent overview called it a
boutique science, at the fringe of stem cell biology. But if it is at
the fringe, why not ban cloning now and have debates about the
other issues in embryonic stem cells later?
It remains possible that someone will solve these programs some-
day. But the prospect of making the cloning procedure efficient,
separating it from the exploitation of women, and deriving cost-ef-
fective therapies from it in your lifetime seems remote.
Second, the political lesson is that while there has been some
misrepresentation in the scientific field, that has been magnified 10
times in the political field, in which in order to get public support
in Government funding, supporters have acted more like snake oil
salesmen than scientists at times, marketing the dream of miracle
cures around the corner.
Researchers are now issuing disclaimers to reduce people’s unre-
alistic expectations about cures and looking for other people to
blame. Some have even blamed the Bush administration for the
failure and fraud in South Korea, as though by opposing cloning,
you are some how making somebody else elsewhere do it wrongly.
But no one has ever done it rightly. To blame unethical cloning in
Korea on those who warned against doing it at all takes blame-
shifting to new depths.
The political lesson is that we need to be aware of the human
cost of this agenda here and now, not only its alleged promise down
the road. And we need to demand evidence for these grandiose
claims.
Third, and most importantly, a moral lesson: Utilitarianism is
not useful. The ethic of the end justifies the means, and particu-
larly the creation and destruction of life in the laboratory in order
to achieve the miracle cures, has unfortunately become almost the
official ethic of those seeking to justify this research.
Government advisory panels have been forced to concede the
early embryo is a developing form of human life, but used a cost/
benefit analysis to argue that cures for born persons is worth more.
As the chief ethicist at the NIH Human Embryo Research Panel
said in 1994, ‘‘If the end doesn’t justify the means, what does?’’
The problem is that the utilitarian ethic relativizes truth just as
quickly as it relativizes lives. If human embryos are lives in a bio-
logical sense but lack the value of persons, could be sacrificed to
help born patients who really matter, then the merely factual truth
can sometimes be sacrificed by the same ethic for the higher truth
of progress. Dr. Hwang did not violate the new ethic of his allies.
He took it to its logical and inevitable conclusion.
By demeaning life, we learn to demean truth, rendering science
itself meaningless. If some researchers have not learned that im-
portant lesson, a sound ethical response must come from society
and its policymakers. That response should begin with a complete
ban on human cloning, and with legislation to prevent the mis-
treatment of women as egg factories for research, or as surrogate
incubators for unborn children grown for their body parts.
Only by respecting fellow human beings of every age and condi-
tion, and by refusing to treat them as mere instruments for achiev-
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ing our research goals, will we promote a human progress worthy
of the name. Thank you.
[The prepared statement of Mr. Doerflinger follows:]
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Ms. FOXX [presiding]. Thank you.
Dr. Mathews.
STATEMENT OF DEBRA J.H. MATHEWS
Ms. MATHEWS. Hello. Thank you very much for having me here
today to share with you some of my thoughts. My name is Debra
Mathews. I am a human geneticist by training. I also have training
in bioethics and science policy.
The first thing I want to say is that nothing—again, reiterate
something that has been said here before today—nothing that Woo
Suk Hwang and his collaborators did or didn’t do has disproved
any of the basic tenets of human embryonic stem cell research, or
taken away any of the potential of the research.
When Woo Suk Hwang and his collaborators were doing this re-
search, parallel research in the United States and other places did
not stop. And the field did not crash and burn with the unfortunate
and reprehensible activities that occurred with Woo Suk Hwang
and his collaborator.
Everyone in the embryonic stem cell research field knew that
this would take a long time, and were surprised when Hwang came
out with the results in 2004 and 2005. And their estimate turned
out to be right. It is going to take time. This research did only
begin in 1998, and that is not when scientists began attempting to
do SCNT. That is when the first human embryonic stem cells were
first derived.
I am going to focus most of my comments on the question of
fraud and the question of egg donation for research. My primary
message here is that oversight is happening, and scientists care
about developing oversight for this research.
SCNT does raise the issue of egg donation for research purposes.
Last summer the National Academy of Sciences issued guidelines,
not only guidelines to govern the research, but also including
guidelines relevant to tissue donors and egg donors.
These guidelines have been broadly adopted by research institu-
tions in the United States. And in addition to the national guide-
lines, the California Institute for Regenerative Medicine has re-
cently issued interim guidelines that go above and beyond the pro-
tections provided by the National Academy’s in their protection of
egg donors.
The California Institute for Regenerative Medicine has also
partnered with the Society for Gynecologic Investigation on a sci-
entific conference this May to focus on the risks of egg donation.
I think that the message from the scientific community on this
issue is very clear. They understand and are prepared to address
the ethical issues raised by stem cell research, including egg dona-
tion for research purposes.
With respect to the question of fraud, again, scientists do not em-
brace fraud. Scientists are slaves to their data, and they want the
data to be as pristine as possible. And fraudulent data is of no use
to the scientific community.
The process of oversight associated with Federal funding pro-
vides some protection against breaches of scientific and ethical in-
tegrity. And the National Academy’s guidelines add additional—
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which, as I mentioned, have been broadly adopted by research in-
stitutions in this country—provide additional oversight.
The National Academy has also announced just recently that
they will be setting up a committee for oversight of stem cell re-
search. Given the lack of Federal funding and therefore the lack of
oversight over this research, the National Academy has taken it
upon themselves to set up an oversight committee specifically for
stem cell research.
The International Society for Stem Cell Research has also set up
a task force to develop internal standards and ethical guidelines for
embryonic stem cell research. And they will be presenting their
findings at the annual meeting in the end of June/beginning of
July.
Finally, recently a group of approximately 60 scientists, ethicists,
lawyers, and policymakers got together and developed a consensus
statement providing recommendations for fostering the ethical and
scientific integrity of embryonic stem cell research in a global con-
text. And I can make those—all of these guidelines available to
you.
Scientists in the United States and around the world recognize
both the promise and the controversy of stem cell research, and
they are willing to step up to the plate and provide and accept ethi-
cal guidance to make sure that this science has the scientific and
ethical integrity that is necessary.
Thank you very much, and I would be happy to answer any ques-
tions.
[The prepared statement of Ms. Mathews follows:]
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Ms. FOXX. Thank you.
Dr. Mathews, I want to ask you one question. And we are nearly
out of time, so we will try to make the questions short and the an-
swers short, too. Has anyone ever created stem cells from cloned
human embryos?
Ms. MATHEWS. Not that I’m aware of.
Ms. FOXX. OK. Has it been done even in monkeys?
Ms. MATHEWS. Monkeys have been very difficult to clone, it is
true.
Ms. FOXX. OK. Is there anyone on the panel who disagrees with
that answer?
Dr. CHOLE. Monkey embryos have been cloned by Gerry Schatten
in Pittsburgh. I don’t—I am not sure if their stem cells have been
extracted and cultured, but the embryos have been made. He is
doing that for reproductive purposes for one way to protect endan-
gered species.
Ms. FOXX. Is he the person who was collaborating with Dr.
Hwang in Korea?
Dr. CHOLE. That is correct.
Ms. MATHEWS. Is it the case that his embryos were basically in
vitro embryos, or were they SCNT embryos?
Dr. CHOLE. They are SCNT embryos. He has had some success
with that. But they have not developed. They have implanted but
not developed.
Ms. FOXX. Dr. Chole, is there any biological difference between
the entity that is created through so-called therapeutic cloning and
reproductive cloning?
Dr. CHOLE. No.
Ms. FOXX. Thank you. OK.
Ms. Norsigian, what have other countries done in the area on
SCNT and egg donation, and what role did a concern for women’s
rights have in the passage of these laws? Do you think the conserv-
ative movement, as we are typically used to thinking about in the
United States, was very active in getting these laws passed? And
what reaction would you have to that?
Ms. NORSIGIAN. Well, I have to say I think it is unfortunate that
the abortion debate and debates about the moral status of the em-
bryo have clouded the discussion of cloning for research purposes
that I focused on in my remarks.
In Canada, interestingly enough, advocates, researchers, people
with differing religious views, sat down and they actually came up
with something that was acceptable to everyone, including the sci-
entists.
And they are putting a moratorium on SCNT. They are not say-
ing never. They are saying, right now we have so much to learn
with other embryo stem cell research. Some of the problems were
just raised: the inability to control differentiation so you get the
kind of tissue type you want, the inability to control tumorigenicity.
I believe that only John Gearhardt and Johns Hopkins has avoid-
ed that by growing the mice embryos to the fetal stage so that
germ line cells were harvested. These are not embryo stem cells.
And in that instance, he was then able to eliminate the issue of
tumorigenicity.
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There are many problems that I think may be able to be over-
come. And those problems can be possibly solved, and you can use
embryo stem cells that would be created from otherwise discarded
embryos from IVF clinics. Though there are reasons, and I mention
them, that make SCNT advantageous, I don’t think they yet justify
the known and unknown risks that we are asking women to under-
go.
There have been similar concerns expressed in England. And it
is interesting. They are allowing this to go forward. The HFEA
there has fairly strict regulations. But there is quite a controversy
about this, particularly as we see some of the harms that women
experience.
Ms. FOXX. We don’t have something—I am.
Ms. Watson.
Ms. WATSON. Are you doing an overhead presentation? Is some-
one doing an overhead?
Ms. FOXX. No. I don’t think it is going to work.
Ms. WATSON. OK. I just want to thank the panelists, and of
course the Chair. I think this has been very enlightening because
it opens up a whole new, I would say, panoply of thought. And I
think these are some of the issues that have been brought up today
that we are going to have to deal with.
I would definitely hate to see conclusions because of some of the
fraud that has been perpetrated stop the serious research that can
save lives, limbs, and improve physical conditions. I would hope
that we could think through and work through the ethical issues,
moral issues, and reach for a higher goal, and that is research that
can improve the quality of life.
So I would look forward—not a question, just a statement—to
further discussions of this type and to the panelists getting back
to us with messages from your research as to the direction the Fed-
eral Government should take.
With that, I want to thank you, Madam Chair, and I will have
to leave. And thank you very much.
Ms. FOXX. Well, Mr. Doerflinger, I want to share some informa-
tion and then ask you a question.
In the district that I represent, there is some absolutely fabulous
and earth-shaking research going on, Baptist Medical Center, with
the use of adult stem cells. The key researcher there said in front
of me and another Member of Congress who was visiting there re-
cently that—in response to a question about why he was not
using—or why he did not advocate the use of embryonic stem cells,
said that—voiced many of the issues that have been voiced here
today, aside from—even aside from religious and ethical issues,
that these lines of stem cells simply created more problems than
they resulted in benefits from.
He and his researchers are able to grow organs that are helping
make massive changes in peoples’ lives. And they are helping our
military people by regeneration of limbs.
Is it your experience, again, that many of the scientists are not
using the embryonic stem cells not for religious purposes but be-
cause of scientific reasons, so that they do not have to ‘‘cloud the
issue’’ by bringing that issue—by bringing the issue of religion into
it?
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Mr. DOERFLINGER. Well, the ethical issue, which I agree with
what was said here earlier about the ethical issue being far broad-
er than any religious issue, is certainly a factor. But I also know
of many researchers who do all of their work on non-embryonic
stem cells simply because they are easier to work with, easier to
control.
In many cases, they do not require lengthy FDA approval be-
cause they are the patients’ own cells. They are not rejected as for-
eign tissue. They are in plentiful supply and can be—the research
is showing they can be multiplied for clinical use more effectively
than used to be the case. And they are working.
Last night, ABC had a premier of its—I guess a new series called
‘‘Miracle Workers’’ featuring a man whose blindness was cured by
his sister’s adult corneal stem cells. And researchers at the Univer-
sity of South Florida, I think, up at St. Elizabeth’s Medical Center
in Massachusetts, have all said, it is not that we object to the eth-
ics of the embryonic cells, it is that these are working and we think
they are going to work better.
And I think it is important to put this in a context that even in
the Clinton administration, the National Bioethics Advisory Com-
mission said that they did realize there is an ethical problem here.
They were willing to override the ethical problem because they
thought that was the only way to go.
But they said that the pursuit of embryonic stem cell research,
even using embryos, spare embryos, from fertility clinics, would not
be justifiable if there were less morally problematic alternatives
available for pursuing the research.
And I think researchers have shown over and over again that
those alternatives are real. They are very promising. And in many
cases, they may well make it unnecessary for us to face these ter-
rible ethical dilemmas.
Ms. FOXX. Thank you very much. I believe that—Mr. Brown.
Mr. BROWN. I would just like to make a comment as a patient
and as a patient advocate. I heard earlier that there are 60 adult
cell cures that have been put in place, some of which I am aware
of. One of them that was mentioned was Parkinson’s.
First, I question if the acid test has actually been made of rep-
lication. I know on some of it, it has—leukemia, for instance. The
first time I heard about the Parkinson’s was 2003. I know of no
Parkinson’s patient who is waiting for embryonic stem cells. If
adult stem cells in truth were doing the job, I would be one of the
happiest people in the world because I would see my wife of 44
years being able to walk 24 hours a day again.
So I think that there is—and I believe that there is a tendency
to overstate a great deal of what this science has and has not ac-
complished from both sides of the issue. I believe there is a great
deal of misstatement, a great deal of miseducation—which I think
it is very important that we educate. And what I would like to see
is a more civil building of consensus and compromise to allow all
of this research to go forward; that we close no doors, and see
where science can take us.
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Ms. FOXX. Thank you all very much for being with us today. The
hearing is adjourned.
[Whereupon, at 5 p.m., the subcommittee was adjourned.]
[Additional information submitted for the hearing record follows:]
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